NZ725151B2 - Methods of preparing a poloxamer for use in cell culture medium - Google Patents
Methods of preparing a poloxamer for use in cell culture medium Download PDFInfo
- Publication number
- NZ725151B2 NZ725151B2 NZ725151A NZ72515115A NZ725151B2 NZ 725151 B2 NZ725151 B2 NZ 725151B2 NZ 725151 A NZ725151 A NZ 725151A NZ 72515115 A NZ72515115 A NZ 72515115A NZ 725151 B2 NZ725151 B2 NZ 725151B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- poloxamer
- minutes
- cell
- cell culture
- heated
- Prior art date
Links
- 229920001983 poloxamer Polymers 0.000 title claims abstract description 648
- 229960000502 Poloxamer Drugs 0.000 title claims abstract description 625
- 239000006143 cell culture media Substances 0.000 title claims abstract description 115
- 229920001184 polypeptide Polymers 0.000 claims abstract description 67
- 210000004027 cells Anatomy 0.000 claims description 168
- 238000010438 heat treatment Methods 0.000 claims description 127
- 230000003833 cell viability Effects 0.000 claims description 79
- 238000004113 cell culture Methods 0.000 claims description 71
- 239000007788 liquid Substances 0.000 claims description 55
- 238000001816 cooling Methods 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 36
- 239000007787 solid Substances 0.000 claims description 30
- 238000003801 milling Methods 0.000 claims description 21
- 230000001965 increased Effects 0.000 claims description 18
- 229920001993 poloxamer 188 Polymers 0.000 claims description 18
- 229920001577 copolymer Polymers 0.000 claims description 15
- 229940044519 Poloxamer 188 Drugs 0.000 claims description 14
- 238000002844 melting Methods 0.000 claims description 12
- 210000004962 mammalian cells Anatomy 0.000 claims description 10
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 10
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 10
- 241000238631 Hexapoda Species 0.000 claims description 8
- 241000699802 Cricetulus griseus Species 0.000 claims description 6
- 210000001672 Ovary Anatomy 0.000 claims description 6
- 239000002609 media Substances 0.000 abstract description 43
- 238000004519 manufacturing process Methods 0.000 abstract description 31
- 108090001123 antibodies Proteins 0.000 description 84
- 102000004965 antibodies Human genes 0.000 description 84
- 230000035899 viability Effects 0.000 description 84
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 239000000523 sample Substances 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 21
- -1 polyoxypropylene Polymers 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 239000000427 antigen Substances 0.000 description 15
- 108091007172 antigens Proteins 0.000 description 14
- 102000038129 antigens Human genes 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000002245 particle Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 230000035693 Fab Effects 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000009529 body temperature measurement Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 229920001451 Polypropylene glycol Polymers 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- 108010045030 monoclonal antibodies Proteins 0.000 description 6
- 102000005614 monoclonal antibodies Human genes 0.000 description 6
- 229920000023 polynucleotide Polymers 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 230000002708 enhancing Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 229960000060 monoclonal antibodies Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 229940088597 Hormone Drugs 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000002900 effect on cell Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003899 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 102100010813 EGF Human genes 0.000 description 3
- 101700033006 EGF Proteins 0.000 description 3
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 3
- 210000004408 Hybridomas Anatomy 0.000 description 3
- 102000018358 Immunoglobulins Human genes 0.000 description 3
- 108060003951 Immunoglobulins Proteins 0.000 description 3
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 3
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 3
- 101700009327 NTF3 Proteins 0.000 description 3
- 102100015697 NTF3 Human genes 0.000 description 3
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 3
- 241000256251 Spodoptera frugiperda Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002826 coolant Substances 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 239000012533 medium component Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002633 protecting Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001603 reducing Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 230000003612 virological Effects 0.000 description 3
- 101700061329 ARTN Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229940047120 Colony stimulating factors Drugs 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000020344 Insulin-Like Growth Factor Binding Proteins Human genes 0.000 description 2
- 108091022066 Insulin-Like Growth Factor Binding Proteins Proteins 0.000 description 2
- 102400000022 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 229940047122 Interleukins Drugs 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 241000235649 Kluyveromyces Species 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 102100016138 NTF4 Human genes 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 210000001322 Periplasm Anatomy 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 229920002511 Poloxamer 237 Polymers 0.000 description 2
- 229920002517 Poloxamer 338 Polymers 0.000 description 2
- 229940044476 Poloxamer 407 Drugs 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 2
- 102100014320 TGFB1 Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102100015249 VEGFA Human genes 0.000 description 2
- 229940029983 VITAMINS Drugs 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012092 media component Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZNAMMSOYKPMPGC-HTOAHKCRSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-(2-phenylethylsulfanyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1SCCC1=CC=CC=C1 ZNAMMSOYKPMPGC-HTOAHKCRSA-N 0.000 description 1
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 1
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 102100014858 AMH Human genes 0.000 description 1
- 101710026933 AMH Proteins 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 101800001866 Atrial natriuretic peptide Proteins 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N Bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 102100013077 CD4 Human genes 0.000 description 1
- 101700022938 CD4 Proteins 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 102100008191 CD8A Human genes 0.000 description 1
- 101700054655 CD8A Proteins 0.000 description 1
- 101710041060 COX7A1 Proteins 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 102100005310 CTLA4 Human genes 0.000 description 1
- 101700054183 CTLA4 Proteins 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 102000027776 ERBB3 Human genes 0.000 description 1
- 101700041204 ERBB3 Proteins 0.000 description 1
- 102100009851 ERBB4 Human genes 0.000 description 1
- 101700023619 ERBB4 Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 102100006624 F9 Human genes 0.000 description 1
- 102100007155 FGF1 Human genes 0.000 description 1
- 101700064732 FGF1 Proteins 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 1
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 101710044881 GHRH Proteins 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229960004666 Glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000006962 Gossypium hirsutum Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000038586 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 102100008240 INHBE Human genes 0.000 description 1
- 101710006573 ITGAL Proteins 0.000 description 1
- 102100019442 ITGAL Human genes 0.000 description 1
- 101710006572 ITGAM Proteins 0.000 description 1
- 102100019441 ITGAM Human genes 0.000 description 1
- 101710006689 ITGAX Proteins 0.000 description 1
- 102100019437 ITGAX Human genes 0.000 description 1
- 101710006663 ITGB2 Proteins 0.000 description 1
- 102100001475 ITGB2 Human genes 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 231100000608 Immunotoxin Toxicity 0.000 description 1
- 108010004484 Immunotoxins Proteins 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 101800001819 Insulin A chain Proteins 0.000 description 1
- 102400000453 Insulin A chain Human genes 0.000 description 1
- 101800000896 Insulin B chain Proteins 0.000 description 1
- 102400000454 Insulin B chain Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 1
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 1
- 108060004448 LPP Proteins 0.000 description 1
- 241000481961 Lachancea thermotolerans Species 0.000 description 1
- 241000235651 Lachancea waltii Species 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 229940040129 Luteinizing Hormone Drugs 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 244000276497 Lycopersicon esculentum Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100008175 MGAM Human genes 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 241000219828 Medicago truncatula Species 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JFTBTTPUYRGXDG-UHFFFAOYSA-N Methyl violet Chemical compound Cl.C1=CC(=NC)C=CC1=C(C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 JFTBTTPUYRGXDG-UHFFFAOYSA-N 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 102100009139 NGF Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101700079360 NTF4 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 229940053128 Nerve Growth Factor Drugs 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 229940032018 Neurotrophin 3 Drugs 0.000 description 1
- 108090000742 Neurotrophin-3 Proteins 0.000 description 1
- 102000004230 Neurotrophin-3 Human genes 0.000 description 1
- 240000008962 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 229950009506 Penicillinase Drugs 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 108010006545 Plantibodies Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 229920002023 Pluronic® F 87 Polymers 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 240000001474 Portulaca oleracea Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229960000856 Protein C Drugs 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101710037934 QRSL1 Proteins 0.000 description 1
- 102100000775 REN Human genes 0.000 description 1
- 101710002944 RLN Proteins 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101800000074 Relaxin A chain Proteins 0.000 description 1
- 102400000834 Relaxin A chain Human genes 0.000 description 1
- 102400000610 Relaxin B chain Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241001123650 Schwanniomyces occidentalis Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000000717 Sertoli cell Anatomy 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infection Diseases 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide Dismutase Proteins 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 1
- 101700038204 TGFA Proteins 0.000 description 1
- 101700041213 TGFB1 Proteins 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 102000006747 Transforming growth factor alpha Human genes 0.000 description 1
- 108010037805 Transforming growth factor beta-1 Proteins 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 240000004652 Vaccinium ovalifolium Species 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 235000017585 alfalfa Nutrition 0.000 description 1
- 235000017587 alfalfa Nutrition 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001455 anti-clotting Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 108020004256 beta-Lactamases Proteins 0.000 description 1
- 102000006635 beta-Lactamases Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 101700018328 ccdB Proteins 0.000 description 1
- 239000012592 cell culture supplement Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960004222 factor IX Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108060002965 flK Proteins 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034448 gene-regulatory proteins Human genes 0.000 description 1
- 108091006088 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002607 hemopoietic Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108010082095 insulin-like growth factor 1, des-(1-3)- Proteins 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 108060005018 mobB Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 108010087335 neurotrophin 5 Proteins 0.000 description 1
- 108090000095 neurotrophin 6 Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002138 osteoinductive Effects 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002496 poly(ether sulfone) Polymers 0.000 description 1
- 229920003208 poly(ethylene sulfide) Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010087851 prorelaxin Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 101710011036 stiI Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 108010042974 transforming growth factor beta4 Proteins 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
- C08G2650/50—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing nitrogen, e.g. polyetheramines or Jeffamines(r)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
- C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
Abstract
Provided herein are methods of preparing a poloxamer for use in a cell culture medium. Also provided herein are cell culture media containing the poloxamer prepared by the methods herein, as well as methods of using the media for cell culturing and polypeptide production from cells.
Description
METHODS OF PREPARING A POLOXAMER FOR USE IN CELL CULTURE MEDIUM
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the priority benefit of U.S. Provisional Application
Serial No. 61/970,281, filed March 25, 2014, which is incorporated herein by reference in
its entirety.
FIELD OF THE INVENTION
This invention generally relates to methods of preparing poloxamer (e.g., for use
in a cell culture medium), cell culture media containing the poloxamer prepared as
described herein, and methods of using the cell culture media described herein to culture
cells and produce polypeptides.
BACKGROUND OF THE INVENTION
Cell culture manufacturing technology is widely used for the production of
protein-based therapeutics, such as antibodies, for use in pharmaceutical formulations.
Commercial production of protein-based products, such as an antibody product, requires
optimization of cell culture parameters in order for the cell to produce a high amount of the
protein product to meet manufacturing demands. When protein-based products are made
on an industrial scale, factors such as the efficiency of protein production and the cost of
raw materials (e.g., the components in the cell culture medium) are critically important.
Poloxamer is a component in cell culture medium that is widely used in
industrial protein production. It is added to a cell culture medium to enhance the viability
of the cultured cells. One of its many functions is to act as a surfactant, reducing the force
of attachment between the cells and gas bubbles in the cell culture medium and protecting
the cells from damage when the bubbles burst. It may also strengthen cell membranes,
improve cell drainage from the foam layer of the culture, and alter bubble frequency and
velocity.
Unfortunately, significant lot-to-lot variability in poloxamer performance has
been observed. When used in a cell culture medium, poorly performing lots of poloxamer
can cause reduced cell viability and cell growth rate. Reduced cell viability leads to
reduced protein production. When culturing is performed on an industrial scale, this
reduced production can result in serious financial losses.
Therefore, a need exists for a simple, inexpensive solution to reduce poloxamer
variability and to improve poloxamer performance, particularly for poorly performing lots.
It is an object of the invention goes some way to addressing this need; and/or or at least to
provide the public with a useful choice.
All publications, patents, and patent applications cited herein are hereby
incorporated by reference in their entirety for all purposes.
SUMMARY OF THE INVENTION
[0007A] In a first aspect, the invention relates to a method of preparing a poloxamer for use
in a cell culture medium, comprising the steps of:
(a) heating a solid poloxamer to at least about 60ºC to form a liquid poloxamer, wherein
the poloxamer is heated to:
(1) between 157ºC and 185°C for at least 1 minute,
(2) between 134ºC and 157ºC for at least 1 minute,
(3) between 120ºC and 134ºC for at least 62 minutes,
(4) between 100ºC and 120ºC for at least 98 minutes,
(5) between 80ºC and 100ºC for at least 122 minutes, or
(6) between 60ºC and 80ºC for at least 143 minutes; and
(b) cooling the liquid poloxamer to a temperature below about 50ºC to form a solid heat-
treated poloxamer, wherein the cooling is not conducted in a prilling or milling device, and
wherein the poloxamer comprises a copolymer of ethylene oxide and propylene oxide.
[0007B] In a second aspect, the invention relates to a method of producing a polypeptide in a
cell culture, comprising:
(a) heating a solid poloxamer to at least about 60ºC to form a liquid poloxamer,
wherein the poloxamer is heated to:
(1) between 157ºC and 185°C for at least 1 minute,
(2) between 134ºC and 157ºC for at least 1 minute,
(3) between 120ºC and 134ºC for at least 62 minutes,
(4) between 100ºC and 120ºC for at least 98 minutes,
(5) between 80ºC and 100ºC for at least 122 minutes, or
(6) between 60ºC and 80ºC for at least 143 minutes; and
(b) cooling the liquid poloxamer to a temperature below about 50ºC to form a solid heat-
treated poloxamer, wherein the cooling is not conducted in a prilling or milling device, and
wherein the poloxamer comprises a copolymer of ethylene oxide and propylene oxide; and
(c) culturing a cell that produces the polypeptide in a cell culture medium under conditions
suitable for production of the polypeptide, wherein the cell culture medium comprises the
cooled polaxamer of step (b).
BRIEF DESCRIPTION OF THE INVENTION
The description herein discloses, inter alia, methods of preparing a poloxamer
(e.g., for use in a cell culture medium). Also described are poloxamers prepared by the
methods described herein. Further disclosed herein are cell culture media compositions
containing a poloxamer prepared by the methods described herein. Further disclosed herein
are methods of producing a polypeptide in a cell culture by culturing a cell that produces
the polypeptide in a cell culture medium containing a poloxamer prepared by the methods
described herein.
Accordingly, in one embodiment, described herein are methods of preparing a
poloxamer for use in a cell culture medium, comprising the steps of: (a) heating a solid
poloxamer to at least about 60ºC to form a liquid poloxamer; and (b) cooling the liquid
poloxamer to a temperature below about 50ºC to form a solid heat-treated poloxamer,
wherein the cooling is not conducted in a prilling or milling device, and wherein the
poloxamer comprises a copolymer of ethylene oxide and propylene oxide. In some
embodiments, cell viability in a cell culture medium comprising the heat-treated poloxamer
is increased as compared to cell viability in a cell culture medium comprising the
poloxamer before step (a). In some embodiments, the poloxamer in step (a) is heated to
between about 60ºC and about 185°C. In some embodiments, the poloxamer in step (a) is
heated to between about 157ºC and about 185°C. In some embodiments, the poloxamer is
heated to between about 157ºC and about 185°C for at least 1 minute. In some
embodiments, the poloxamer is heated to between about 157ºC and about 185°C for
between 1 minute and about 250 minutes. In some embodiments, the poloxamer in step (a)
is heated to between about 134ºC and about 157ºC. In some embodiments, the poloxamer
is heated to between about 134ºC and about 157ºC for at least 1 minute. In some
embodiments, the poloxamer is heated to between about 134ºC and about 157ºC for
between 1 minute and about 250 minutes. In some embodiments, the poloxamer in step (a)
is heated to between about 120ºC and about 134ºC. In some embodiments, the poloxamer
is heated to between about 120ºC and about 134ºC for at least about 62 minutes. In some
embodiments, the poloxamer is heated to between about 120ºC and about 134ºC for
between about 62 minutes and about 250 minutes. In some embodiments, the poloxamer in
step (a) is heated to between about 100ºC and about 120ºC. In some embodiments, the
poloxamer is heated to between about 100ºC and about 120ºC for at least about 98 minutes.
In some embodiments, the poloxamer is heated to between about 100ºC and about 120ºC
for between about 98 minutes and about 250 minutes. In some embodiments, the
poloxamer in step (a) is heated to between about 80ºC and about 100ºC. In some
embodiments, the poloxamer is heated to between about 80ºC and about 100ºC for at least
about 122 minutes. In some embodiments, the poloxamer is heated to between about 80ºC
and about 100ºC for between about 122 minutes and about 250 minutes. In some
embodiments, the poloxamer in step (a) is heated to between about 60ºC and about 80ºC.
In some embodiments, the poloxamer is heated to between about 60ºC and about 80ºC for
at least about 143 minutes. In some embodiments, the poloxamer is heated to between
about 60ºC and about 80ºC for between about 143 minutes and about 250 minutes. In some
embodiments, cell viability in a cell culture medium comprising the heat-treated poloxamer
is increased by at least 10% as compared to cell viability in a cell culture medium
comprising the poloxamer before step (a). In some embodiments, the cell viability is
increased by at least about 20%. In some embodiments, the cell viability is increased by at
least about 30%. In some embodiments, the cell viability in a cell culture medium
comprising the poloxamer before step (a) is below about 80% after about 3 hours of cell
culturing. In some embodiments, the liquid poloxamer in step (b) is cooled at ambient
temperature, about 2ºC to about 8ºC, or below 0ºC. In some embodiments, the poloxamer
is heated under a vacuum. In some embodiments, the liquid poloxamer is cooled for at least
about 20 minutes. In some embodiments, the heated-treated poloxamer produced in step
(b) is added into a cell culture medium. In some embodiments, steps (a) and (b) are
repeated at least once before adding the heated-treated poloxamer into the cell culture
medium. In some embodiments, the poloxamer has been treated by a prilling process
before step (a). In some embodiments, the poloxamer has a formula of
HO(C2H4O)n(C3H6O)m(C2H4O)nH, wherein n is from about 60 to about 150 and m is from
about 25 to about 60. In some embodiments, the poloxamer has a melting temperature of
about 55ºC. In some embodiments, the poloxamer has an average molecular weight of
from about 6,000 to about 18,000 Daltons. In some embodiments, the poloxamer
comprises a copolymer having a formula of HO(C H O) (C H O) (C H O) H with n
2 4 n 3 6 m 2 4 n
having a value of about 80, with m having a value of about 27, and the poloxamer has an
average molecular weight of from about 7680 to about 9510 g/mol. In some embodiments,
the poloxamer is poloxamer 188. In some embodiments, the cell is a mammalian cell. In
some embodiments, the cell is a Chinese Hamster Ovary (CHO) cell. In some
embodiments, the cell is an insect cell. In some embodiments, the cell produces a
polypeptide.
In another embodiment, described herein is a poloxamer prepared by any of the
methods described above and herein.
In a further embodiment, described herein is a cell culture medium comprising
the poloxamer prepared by any of the methods described above and herein. In some
embodiments, the cell medium comprises the heat-treated poloxamer at about 0.1 g/L to
about 10 g/L. In some embodiments, the cell medium comprises the heat-treated
poloxamer at about 0.1 g/L to about 3 g/L. In some embodiments, the cell medium
comprises the heat-treated poloxamer at about 3 g/L to about 10 g/L.
In a still further embodiment, described herein are methods of producing a
polypeptide in a cell culture, comprising the step of culturing a cell that produces the
polypeptide in a cell culture medium under conditions suitable for production of the
polypeptide, wherein the cell culture medium comprises the poloxamer produced by any of
the methods described above and herein. In some embodiments, the cell is a mammalian
cell. In some embodiments, the cell is a Chinese Hamster Ovary (CHO) cell. In some
embodiments, the cell is an insect cell. In some embodiments, the cell medium comprises
the heat-treated poloxamer at about 0.1 g/L to about 10 g/L. In some embodiments, the cell
medium comprises the heat-treated poloxamer at about 0.1 g/L to about 3 g/L. In some
embodiments, the cell medium comprises the heat-treated poloxamer at about 3 g/L to
about 10 g/L. In some embodiments, the polypeptide is an antibody or antigen-binding
fragment thereof.
Accordingly, in one embodiment, described herein are methods of preparing a
poloxamer (e.g., for use in a cell culture medium), comprising the steps of (a) heating a
purified poloxamer to about 80ºC or above (e.g., about 80ºC to about 100ºC) to form a
liquid poloxamer, and (b) cooling the liquid poloxamer to a temperature at about 50ºC or
below to form a solid heat-treated poloxamer, wherein the cooling is not conducted in a
prilling or milling device. In some embodiments, the poloxamer comprises a copolymer of
ethylene oxide and propylene oxide. In some embodiments, the poloxamer comprises a
copolymer of ethylene oxide and propylene oxide having a formula of
HO(C H O) (C H O) (C H O) H, wherein n is from about 60 to about 150 and m is from
2 4 n 3 6 m 2 4 n
about 25 to about 60. In some embodiments, cell viability in a cell culture medium
comprising the heat-treated poloxamer is increased as compared to cell viability in a cell
culture medium comprising the poloxamer before step (a). In some embodiments, the
poloxamer is a purified poloxamer. In some embodiments, a purified poloxamer is a
poloxamer composition that does not contain another therapeutic or pharmaceutical
compound. In some embodiments, the poloxamer in step (a) does not contain another
therapeutic or pharmaceutical compound. In some embodiments, the poloxamer in step (a)
is heated to about 85ºC to about 91ºC. In some embodiments herein, the poloxamer is
heated from about 10 to about 15 minutes. In some embodiments herein, the liquid
poloxamer in step (b) is cooled at ambient temperature, about 2ºC to about 8ºC, or below
0ºC. In some embodiments herein, the liquid poloxamer is cooled for at least about 20
minutes. In some embodiments herein, the heated-treated poloxamer produced in step (b) is
added into a cell culture medium. In some embodiments herein, steps (a) and (b) are
repeated at least once before adding the heated-treated poloxamer into the cell culture
medium. In some embodiments herein, the cell viability is increased by at least about 10%.
In some embodiments herein, the cell viability is increased by at least about 30%. In some
embodiments herein, the cell viability in a cell culture medium comprising the poloxamer
before step (a) is below about 80%. In some embodiments herein, the poloxamer has been
treated by a prilling process before step (a). In some embodiments herein, the poloxamer
has a melting temperature in the range of about 45ºC to about 60ºC. In some embodiments
herein, the poloxamer has an average molecular weight of from about 6,000 to about 18,000
Daltons. In some embodiments herein, the poloxamer is poloxamer 188. In some
embodiments, the poloxamer comprises a copolymer having a formula of
HO(C2H4O)n(C3H6O)m(C2H4O)nH with n having a value of about 80, with m having a value
of about 27, and the poloxamer has an average molecular weight of from about 7680 to
about 9510 g/mol. In some embodiments herein, the poloxamer is poloxamer 237. In some
embodiments, the poloxamer comprises a copolymer having a formula of
HO(C H O) (C H O) (C H O) H with n having a value of about 64 and with m having a
2 4 n 3 6 m 2 4 n
value of about 37. In some embodiments herein, the poloxamer is poloxamer 338. In some
embodiments, the poloxamer comprises a copolymer having a formula of
HO(C H O) (C H O) (C H O) H with n having a value of about 141 and with m having a
2 4 n 3 6 m 2 4 n
value of about 44. In some embodiments herein, the poloxamer is poloxamer 407. In some
embodiments, the poloxamer comprises a copolymer having a formula of
HO(C H O) (C H O) (C H O) H with n having a value of about 101 and with m having a
2 4 n 3 6 m 2 4 n
value of about 56. In some embodiments herein, the cell may be a mammalian cell. In
some embodiments, the cell may be a Chinese Hamster Ovary (CHO) cell. In some
embodiments herein, the cell may be an insect cell. In some embodiments herein, the cell
produces a polypeptide. In some embodiments, the polypeptide is an antibody or antigen-
binding fragment thereof. In another embodiment, described herein is a poloxamer
produced by any of the methods described above and herein.
In another embodiment, described herein are cell culture media comprising the
poloxamer produced by any of the methods described above and herein. In some
embodiments, the cell medium comprises the heat-treated poloxamer at about 0.1 g/L to
about 10 g/L. In some embodiments, the cell medium comprises the heat-treated
poloxamer at about 0.1 g/L to about 3 g/L. In some embodiments, the cell medium
comprises the heat-treated poloxamer at about 3 g/L to about 10 g/L.
In another embodiment, described herein are methods of producing a
polypeptide in a cell culture, comprising the step of culturing a cell that produces the
polypeptide in a cell culture medium under conditions suitable for production of the
polypeptide, wherein the cell culture medium comprises the poloxamer produced by any of
the methods described above and herein. In some embodiments, the cell is a mammalian
cell. In some embodiments, the cell is a Chinese Hamster Ovary (CHO) cell. In some
embodiments, the cell is an insect cell. In some embodiments, the cell medium comprises
the heat-treated poloxamer at about 0.1 g/L to about 10 g/L. In some embodiments, the cell
medium comprises the heat-treated poloxamer at about 0.1 g/L to about 3 g/L. In some
embodiments, the cell medium comprises the heat-treated poloxamer at about 3 g/L to
about 10 g/L. In some embodiments, the polypeptide produced by the cell is an antibody or
antigen-binding fragment thereof.
It is to be understood that one, some, or all of the properties of the various
embodiments described herein may be combined to form other embodiments of the present
invention. These and other aspects of the invention will become apparent to one of skill in
the art.
[0016A] Certain statements that appear herein are broader than what appears in the
statements of the invention. These statements are provided in the interests of providing the
reader with a better understanding of the invention and its practice. The reader is directed to
the accompanying claim set which defines the scope of the invention.
[0016B] In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission that
such documents, or such sources of information, in any jurisdiction, are prior art, or form
part of the common general knowledge in the art.
BRIEF DESCRIPTION OF THE DRAWINGS
shows that heat treatment of poloxamer improves its effect on cell
viability in culture. The diamond plot indicates the mean (center line) and upper/lower
95% confidence intervals (points of diamonds), as well as the cell viability values (dots) for
each experimental condition. Each experiment compares untreated and heat-treated (HT)
poloxamer from a good or bad (“suspect”) poloxamer lot, as indicated on the x-axis.
Arrows indicate improvement in cell viability upon heat treatment of bad lots. Note that
heat treatment also improved the cell viability of the good lot, from an average of
approximately 85% to a value of approximately 95%.
shows cell viability (%) in a high shear shake flask model (HSSF) test
for untreated and heat treated (_HT) poloxamer samples A, B, and C (see also Table 2).
shows the response surface design of conditions tested in ovens. Each
condition is labeled in the format “time, temperature.” Conditions marked with ‘♦’ were
tested in HSSF. Conditions marked with ‘◊’ were prepared in ovens but not tested in HSSF.
Temperature (in ºC) represents the set temperature of the oven, while time (in min)
represents the time the poloxamer sample was in the oven.
shows the improvement in cell viability (%)(Vf – Vf ) for
(treated) (untreated)
samples of C poloxamer heat treated in ovens under the indicated conditions, compared to
positive (“Good lot”) and negative (“Untreated bad lot”) controls (D and C, respectively).
Error bars depict one standard deviation.
shows a contour plot from a full design of experiments (DOE) exploring
effects of different heat treatment conditions on poloxamer performance in cell culture.
Viability improvement (Vf – Vf ) in the HSSF test is shown as a function of
(treated) (untreated)
time and temperature. Dots indicate sample conditions tested.
shows improvement in cell viability (%)(Vf – Vf ) in a
(treated) (untreated)
HSSF test for poloxamer samples from three bad lots (H, F, and G) and one good lot (E)
heat treated under the indicated conditions.
shows a comparison of improvement in cell viability (%) (Vf (treated) – Vf (untreated)) for
bad poloxamer lots (H and G) treated at low temperatures (60-80°C) for a long duration (120
min). * HSSF model run in duplicates.
shows the improvement in cell viability (%)(Vf – Vf ) in a
(treated) (untreated)
HSSF test for poloxamer samples (H and G) heat treated under vacuum conditions, as
compared to untreated.
shows heating and cooling profiles for poloxamer material in ovens.
Three temperatures were tested: 140ºC, 155ºC, and 170ºC. Once the temperature readout
began to stabilize, material was removed from the oven and cooled at room temperature.
Profiles leveled off at 40ºC, near the melting point of poloxamer.
shows student’s t-test results for each lot of heat treated poloxamer
compared to the positive control (D) and untreated material. Mean diamonds illustrate 95%
confidence intervals (upper and lower points) and mean (center line) for each data set.
shows a contour plot for data from response surface and full DOE
experiments illustrating the large working range for poloxamer heat treatment conditions.
Change in cell viability (%) for each experimental space is illustrated. Viability
improvement (Vf – Vf ) in the HSSF test is shown as a function of time and
(treated) (untreated)
temperature. Response surface data reflects incubation times and temperatures corrected
for time required to reach target temperature. Dots indicate sample conditions tested.
DETAILED DESCRIPTION
The inventors of this application demonstrated that heat treatment of poloxamer
improves the ability of the poloxamer to support viability in cell culture. The data in the
application show that using a cell culture medium with the heat-treated poloxamer improves
cell viability, compared to using a cell culture medium without the heat treatment. The
inventors demonstrated that different lots of poloxamer, when added to cell culture
medium, have dramatically different effects on cell viability, and that the heat treatment
described herein improves the effect on cell viability for both good and bad lots of
poloxamer.
In one embodiment, described herein are methods for preparing a poloxamer by
heating a poloxamer and cooling the poloxamer, where the cooling is not conducted in a
prilling or milling device. In some embodiments, the methods include preparing a
poloxamer by heating a poloxamer to about 80ºC or above (e.g., to about 100ºC) to form a
liquid poloxamer and cooling the liquid poloxamer to a temperature below about 50ºC to
form a solid heat-treated poloxamer, where the cooling is not conducted in a prilling or
milling device, and where the poloxamer contains a copolymer of ethylene oxide and
propylene oxide. In some embodiments, the poloxamer contains a copolymer of ethylene
oxide and propylene oxide having a formula of HO(C H O) (C H O) (C H O) H, where n
2 4 n 3 6 m 2 4 n
is from about 60 to about 150 and m is from about 25 to about 60. In some embodiments,
the poloxamer is a solid poloxamer before the heating and cooling process. In some
embodiments, the poloxamer is a liquid poloxamer at room temperature before the heating
and cooling process. In some embodiments, the poloxamer is a solid poloxamer dissolved
in a liquid or aqueous solution before the heating and cooling process. For example, the
methods described herein may be used to prepare a poloxamer for use in a cell culture or
cell culture medium.
In another embodiment, described herein are compositions for cell culture
including a heat-treated poloxamer. In another aspect, described herein are compositions
for cell culture containing a heat-treated poloxamer in a cell culture medium.
In another embodiment, described herein are methods for producing a
polypeptide in a cell culture by culturing a cell that produces the polypeptide in a cell
culture medium containing a heat-treated poloxamer under conditions suitable for
production of the polypeptide.
I. Definitions
Before describing the invention in detail, it is to be understood that this
invention is not limited to particular compositions or biological systems, which can, of
course, vary. It is also to be understood that the terminology used herein is for the purpose
of describing particular embodiments only, and is not intended to be limiting.
As used in this specification and the appended claims, the singular forms “a”,
“an” and “the” include plural referents unless the content clearly dictates otherwise. Thus,
for example, reference to “a molecule” optionally includes a combination of two or more
such molecules, and the like.
The term “about” as used herein refers to the usual error range for the respective
value readily known to the skilled person in this technical field. Reference to “about” a
value or parameter herein includes (and describes) embodiments that are directed to that
value or parameter per se.
It is understood that aspects and embodiments of the invention described herein
include “comprising,” “consisting,” and “consisting essentially of” aspects and
embodiments.
[0034A] The term “comprising” as used in this specification and claims means “consisting
at least in part of”. When interpreting statements in this specification, and claims which
include the term “comprising”, it is to be understood that other features that are additional
to the features prefaced by this term in each statement or claim may also be present.
Related terms such as “comprise” and “comprised” are to be interpreted in similar manner.
The term “poloxamer” refers to a block copolymer made of a chain of
polyoxypropylene (the term “propylene oxide” may be used interchangeably herein)
flanked by two chains of polyoxyethylene (the term “ethylene oxide” may be used
interchangeably herein). Poloxamers may be sold under trade names including
® ® ® ®
PLURONIC (BASF), KOLLIPHOR (BASF), LUTROL (BASF), and SYNPERONIC
(Croda International). Unless a particular poloxamer species is specified, references to
“poloxamer” may generically refer to multiple poloxamer species.
In some embodiments, the poloxamer is a purified poloxamer. The term
“purified poloxamer” refers to a poloxamer composition that is substantially free from other
compounds. A purified poloxamer may include, for example, a commercially available
poloxamer having a grade of technical or higher. Examples of grades of technical or higher
may include technical grade, purified grade, N.F. grade (US National Formulary), U.S.P.
grade (US Pharmacopeia), reagent grade, and A.C.S. grade (American Chemical Society).
A purified poloxamer refers to one that is not mixed with another compound. For example,
a purified poloxamer may refer to a poloxamer that is not mixed with a therapeutic or
pharmaceutical compound, e.g., as part of a drug formulation. In some embodiments, a
purified poloxamer is one that is substantially free from, or not mixed with, unreacted
reactants, catalysts or other products generated through a poloxamer synthesis process or
reaction.
The term “heat-treated poloxamer” refers to a poloxamer heat treated at least
once by the methods described herein.
The terms “medium” and “cell culture medium” refer to a nutrient source used
for growing or maintaining cells. As is understood by a person of skill in the art, the
nutrient source may contain components required by the cell for growth and/or survival or
may contain components that aid in cell growth and/or survival. Vitamins, essential or non-
essential amino acids, trace elements, and surfactants (e.g., poloxamers) are examples of
medium components. Any media described herein may also be supplemented with any one
or more of insulin, plant hydrolysates and animal hydrolysates.
“Culturing” a cell refers to contacting a cell with a cell culture medium under
conditions suitable to the viability and/or growth and/or proliferation of the cell.
“Batch culture” refers to a culture in which all components for cell culturing
(including the cells and all culture nutrients and components) are supplied to the culturing
vessel at the start of the culturing process.
The phrase “fed batch cell culture,” as used herein refers to a batch culture
wherein the cells and culture medium are supplied to the culturing vessel initially, and
additional culture nutrients are fed, continuously or in discrete increments, to the culture
during the culturing process, with or without periodic cell and/or product harvest before
termination of culture.
“Perfusion culture” is a culture by which the cells are restrained in the culture
by, e.g., filtration, encapsulation, anchoring to microcarriers, etc., and the culture medium is
continuously or intermittently introduced and removed from the culturing vessel.
“Culturing vessel” refers to a container used for culturing a cell. The culturing
vessel can be of any size so long as it is useful for the culturing of cells.
The terms “polypeptide” and “protein” are used interchangeably herein to refer
to polymers of amino acids of any length. The polymer may be linear or branched, it may
comprise modified amino acids, and it may be interrupted by non-amino acids. The terms
also encompass an amino acid polymer that has been modified naturally or by intervention;
for example, disulfide bond formation, glycosylation, lipidation, acetylation,
phosphorylation, or any other manipulation or modification, such as conjugation with a
labeling component. Also included within the definition are, for example, polypeptides
containing one or more analogs of an amino acid (including, for example, unnatural amino
acids, etc.), as well as other modifications known in the art. Examples of polypeptides
encompassed within the definition herein include mammalian proteins, such as, e.g., renin;
a growth hormone, including human growth hormone and bovine growth hormone; growth
hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins;
alphaantitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating
hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC,
factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C;
atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or
human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic
growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated
on activation normally T-cell expressed and secreted); human macrophage inflammatory
protein (MIPalpha); a serum albumin such as human serum albumin; Muellerian-
inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-
associated peptide; a microbial protein, such as beta-lactamase; DNase; IgE; a cytotoxic T-
lymphocyte associated antigen (CTLA), such as CTLA-4; inhibin; activin; vascular
endothelial growth factor (VEGF); receptors for hormones or growth factors; protein A or
D; rheumatoid factors; a neurotrophic factor such as bone-derived neurotrophic factor
(BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve growth
factor such as NGF-b; platelet-derived growth factor (PDGF); fibroblast growth factor such
as aFGF and bFGF; epidermal growth factor (EGF); transforming growth factor (TGF) such
as TGF-alpha and TGF-beta, including TGF-β1, TGF-β2, TGF-β3, TGF-β4, or TGF-β5;
insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-3)-IGF-I (brain IGF-I),
insulin-like growth factor binding proteins (IGFBPs); CD proteins such as CD3, CD4, CD8,
CD19 and CD20; erythropoietin; osteoinductive factors; immunotoxins; a bone
morphogenetic protein (BMP); an interferon such as interferon-alpha, -beta, and -gamma;
colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF; interleukins (ILs),
e.g., IL-1 to IL-10; superoxide dismutase; T-cell receptors; surface membrane proteins;
decay accelerating factor; viral antigen such as, for example, a portion of the AIDS
envelope; transport proteins; homing receptors; addressins; regulatory proteins; integrins
such as CD11a, CD11b, CD11c, CD18, an ICAM, VLA-4 and VCAM; a tumor associated
antigen such as CA125 (ovarian cancer antigen) or HER2, HER3 or HER4 receptor;
immunoadhesins; and fragments and/or variants of any of the above-listed proteins as well
as antibodies, including antibody fragments, binding to a protein, including, for example,
any of the above-listed proteins.
The term “titer” as used herein refers to the total amount of recombinantly
expressed antibody produced by a cell culture divided by a given amount of medium
volume. Titer is typically expressed in units of milligrams of antibody per milliliter of
medium. Titer can be expressed or assessed in terms of a relative measurement, such as a
percentage increase in titer as compared obtaining the protein product under different
culture conditions.
The term “antibody” herein is used in the broadest sense and specifically covers
monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies,
multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they
exhibit the desired biological activity. An antibody can be human, humanized and/or
affinity matured.
The terms “full length antibody,” “intact antibody” and “whole antibody” are
used herein interchangeably to refer to an antibody in its substantially intact form, not
antibody fragments as defined below. The terms particularly refer to an antibody with
heavy chains that contain an Fc region.
“Antibody fragments” comprise a portion of an intact antibody, preferably
comprising the antigen binding region (the term “antigen-binding fragment” may be used
interchangeably) thereof. Examples of antibody fragments include Fab, Fab’, F(ab’) , and
Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and
multispecific antibodies formed from antibody fragments.
II. Methods of Preparing a Poloxamer
Described herein are methods of preparing a poloxamer, for example, for use in
a cell culture medium.
Heating
In some embodiments, the methods of preparing a poloxamer for use in a cell
culture medium described herein include heating a poloxamer (e.g., a purified poloxamer)
to form a liquid poloxamer. For example, a purified poloxamer in the solid phase may be
heated to melt, thereby forming a liquid poloxamer. The temperature to which the
poloxamer is heated may be adjusted based upon the melting temperature of the particular
poloxamer species used. In some embodiments, the purified poloxamer has a melting
temperature in the range of about 45ºC to about 60ºC. In some embodiments, the purified
poloxamer has a melting temperature in the range of about 50ºC to about 55ºC.
In some embodiments, the methods of preparing a poloxamer for use in a cell
culture medium described herein include heating a solid poloxamer to at least about 60ºC to
form a liquid poloxamer and cooling the liquid poloxamer to a temperature below about
50ºC to form a solid heat-treated poloxamer, where the cooling is not conducted in a
prilling or milling device, and the poloxamer comprises a copolymer of ethylene oxide and
propylene oxide. In some embodiments, the poloxamer is a purified poloxamer. In some
embodiments, a purified poloxamer is a poloxamer composition that does not contain
another therapeutic or pharmaceutical compound.
In some embodiments, the poloxamer (e.g., a purified poloxamer) is heated to at
least about any of the following temperatures (in ºC): 60, 65, 70, 75, 80, 85, 90, 95, 100,
105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, or 185. In
some embodiments, the poloxamer (e.g., a purified poloxamer) is heated for at least 1
minute. In some embodiments, the poloxamer is heated for at least about 1 minute, at least
about 2 minutes, at least about 3 minutes, at least about 4 minutes, at least about 5 minutes,
at least about 6 minutes, at least about 7 minutes, at least about 8 minutes, at least about 9
minutes, at least about 10 minutes, at least about 15 minutes, at least about 20 minutes, at
least about 25 minutes, at least about 30 minutes, at least about 35 minutes, at least about 40
minutes, at least about 45 minutes, at least about 50 minutes, at least about 55 minutes, at
least about 60 minutes, at least about 65 minutes, at least about 70 minutes, at least about 75
minutes, at least about 80 minutes, at least about 85 minutes, at least about 90 minutes, at
least about 100 minutes, at least about 110 minutes, at least about 120 minutes, at least
about 130 minutes, at least about 140 minutes, at least about 150 minutes, at least about 160
minutes, at least about 170 minutes, at least about 180 minutes, at least about 190 minutes,
at least about 200 minutes, at least about 210 minutes, at least about 220 minutes, at least
about 230 minutes, or at least about 240 minutes.
In some embodiments, the poloxamer (e.g., a purified poloxamer) is heated to
between about 60ºC and about 185°C. It is to be noted that any of the temperature ranges
described herein are meant to be inclusive, unless explicitly stated otherwise. For example,
a range of temperatures between about 60ºC and about 185°C includes about 60ºC and
about 185°C as being within said range. In some embodiments, the poloxamer is heated to
a temperature less than about any of the following temperatures (in ºC): 185, 180, 175, 170,
165, 160, 155, 150, 145, 140, 135, 130, 125, 120, 115, 110, 105, 100, 95, 90, 85, 80, 75, 70,
or 65. In some embodiments, the poloxamer is heated to a temperature greater than about
any of the following temperatures (in ºC): 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115,
120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, or 180. That is, the poloxamer
may be heated to a temperature in the range of temperatures having an upper limit of 185,
180, 175, 170, 165, 160, 155, 150, 145, 140, 135, 130, 125, 120, 115, 110, 105, 100, 95, 90,
85, 80, 75, 70, or 65 and an independently selected lower limit of 60, 65, 70, 75, 80, 85, 90,
95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, or 180,
wherein the lower limit is less than the upper limit. In some embodiments, the poloxamer
(e.g., a purified poloxamer) is heated to between about 60ºC and about 185°C for at least 1
minute. In some embodiments, the poloxamer is heated for at least about 1 minute, at least
about 2 minutes, at least about 3 minutes, at least about 4 minutes, at least about 5 minutes,
at least about 6 minutes, at least about 7 minutes, at least about 8 minutes, at least about 9
minutes, at least about 10 minutes, at least about 15 minutes, at least about 20 minutes, at
least about 25 minutes, at least about 30 minutes, at least about 35 minutes, at least about 40
minutes, at least about 45 minutes, at least about 50 minutes, at least about 55 minutes, at
least about 60 minutes, at least about 65 minutes, at least about 70 minutes, at least about 75
minutes, at least about 80 minutes, at least about 85 minutes, at least about 90 minutes, at
least about 100 minutes, at least about 110 minutes, at least about 120 minutes, at least
about 130 minutes, at least about 140 minutes, at least about 150 minutes, at least about 160
minutes, at least about 170 minutes, at least about 180 minutes, at least about 190 minutes,
at least about 200 minutes, at least about 210 minutes, at least about 220 minutes, at least
about 230 minutes, or at least about 240 minutes. In some embodiments, the poloxamer is
heated to between about 60ºC and about 185°C for between about 1 minute and about 250
minutes. It is to be noted that any of the time ranges described herein are meant to be
inclusive, unless explicitly stated otherwise. For example, a range of times between about 1
minute and about 250 minutes includes about 1 minute and about 250 minutes as being
within said range. In some embodiments, the poloxamer is heated for less than about any of
the following times (in minutes): 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150,
140, 130, 120, 110, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10,
9, 8, 7, 6, 5, 4, 3, or 2. In some embodiments, the poloxamer is heated for greater than
about any of the following times (in minutes): 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180,
190, 200, 210, 220, 230, or 240. That is, the poloxamer may be heated for a time in the
range of times having an upper limit of 250, 240, 230, 220, 210, 200, 190, 180, 170, 160,
150, 140, 130, 120, 110, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20,
, 10, 9, 8, 7, 6, 5, 4, 3, or 2 and an independently selected lower limit of 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130,
140, 150, 160, 170, 180, 190, 200, 210, 220, 230, or 2400, wherein the lower limit is less
than the upper limit.
In some embodiments, the poloxamer (e.g., a purified poloxamer) is heated to
between about 157ºC and about 185°C. In some embodiments, the poloxamer is heated to a
temperature less than about any of the following temperatures (in ºC): 185, 180, 175, 170,
165, or 160. In some embodiments, the poloxamer is heated to a temperature greater than
about any of the following temperatures (in ºC): 157, 160, 165, 170, 175, or 180. That is,
the poloxamer may be heated to a temperature in the range of temperatures having an upper
limit of 185, 180, 175, 170, 165, or 160 and an independently selected lower limit of 157,
160, 165, 170, 175, or 180, wherein the lower limit is less than the upper limit. In some
embodiments, the poloxamer is heated to between about 157ºC and about 185°C for at least
about 1 minute, at least about 2 minutes, at least about 3 minutes, at least about 4 minutes,
at least about 5 minutes, at least about 6 minutes, at least about 7 minutes, at least about 8
minutes, at least about 9 minutes, at least about 10 minutes, at least about 15 minutes, at
least about 20 minutes, at least about 25 minutes, at least about 30 minutes, at least about 35
minutes, at least about 40 minutes, at least about 45 minutes, at least about 50 minutes, at
least about 55 minutes, at least about 60 minutes, at least about 65 minutes, at least about 70
minutes, at least about 75 minutes, at least about 80 minutes, at least about 85 minutes, at
least about 90 minutes, at least about 100 minutes, at least about 110 minutes, at least about
120 minutes, at least about 130 minutes, at least about 140 minutes, at least about 150
minutes, at least about 160 minutes, at least about 170 minutes, at least about 180 minutes,
at least about 190 minutes, at least about 200 minutes, at least about 210 minutes, at least
about 220 minutes, at least about 230 minutes, or at least about 240 minutes. In some
embodiments, the poloxamer is heated to between about 157ºC and about 185°C for less
than or equal to 250 minutes.
In some embodiments, the poloxamer (e.g., a purified poloxamer) is heated to
between about 134ºC and about 157°C. In some embodiments, the poloxamer is heated to a
temperature less than about any of the following temperatures (in ºC): 157, 155, 150, 145,
140, or 135. In some embodiments, the poloxamer is heated to a temperature greater than
about any of the following temperatures (in ºC): 134, 135, 140, 145, 150, or 155. That is,
the poloxamer may be heated to a temperature in the range of temperatures having an upper
limit of 157, 155, 150, 145, 140, or 135 and an independently selected lower limit of 134,
135, 140, 145, 150, or 155, wherein the lower limit is less than the upper limit. In some
embodiments, the poloxamer is heated to between about 134ºC and about 157°C for at least
about 1 minute, at least about 2 minutes, at least about 3 minutes, at least about 4 minutes,
at least about 5 minutes, at least about 6 minutes, at least about 7 minutes, at least about 8
minutes, at least about 9 minutes, at least about 10 minutes, at least about 15 minutes, at
least about 20 minutes, at least about 25 minutes, at least about 30 minutes, at least about 35
minutes, at least about 40 minutes, at least about 45 minutes, at least about 50 minutes, at
least about 55 minutes, at least about 60 minutes, at least about 65 minutes, at least about 70
minutes, at least about 75 minutes, at least about 80 minutes, at least about 85 minutes, at
least about 90 minutes, at least about 100 minutes, at least about 110 minutes, at least about
120 minutes, at least about 130 minutes, at least about 140 minutes, at least about 150
minutes, at least about 160 minutes, at least about 170 minutes, at least about 180 minutes,
at least about 190 minutes, at least about 200 minutes, at least about 210 minutes, at least
about 220 minutes, at least about 230 minutes, or at least about 240 minutes. In some
embodiments, the poloxamer is heated to between about 134ºC and about 157°C for less
than or equal to 250 minutes.
In some embodiments, the poloxamer (e.g., a purified poloxamer) is heated to
between about 120ºC and about 134°C. In some embodiments, the poloxamer is heated to a
temperature less than about any of the following temperatures (in ºC): 134, 130, or 125. In
some embodiments, the poloxamer is heated to a temperature greater than about any of the
following temperatures (in ºC): 120, 125, or 130. That is, the poloxamer may be heated to a
temperature in the range of temperatures having an upper limit of 134, 130, or 125 and an
independently selected lower limit of 120, 125, or 130, wherein the lower limit is less than
the upper limit. In some embodiments, the poloxamer is heated to between about 120ºC
and about 134°C for at least about 20 minutes, at least about 30 minutes, at least about 40
minutes, at least about 50 minutes, or at least about 60 minutes. In some embodiments, the
poloxamer is heated to between about 120ºC and about 134°C for at least about 62 minutes,
at least about 65 minutes, at least about 70 minutes, at least about 75 minutes, at least about
80 minutes, at least about 85 minutes, at least about 90 minutes, at least about 100 minutes,
at least about 110 minutes, at least about 120 minutes, at least about 130 minutes, at least
about 140 minutes, at least about 150 minutes, at least about 160 minutes, at least about 170
minutes, at least about 180 minutes, at least about 190 minutes, at least about 200 minutes,
at least about 210 minutes, at least about 220 minutes, at least about 230 minutes, or at least
about 240 minutes. In some embodiments, the poloxamer is heated to between about 120ºC
and about 134°C for less than or equal to 250 minutes.
In some embodiments, the poloxamer (e.g., a purified poloxamer) is heated to
between about 100ºC and about 120°C. In some embodiments, the poloxamer is heated to a
temperature less than about any of the following temperatures (in ºC): 120, 115, 110, or
105. In some embodiments, the poloxamer is heated to a temperature greater than about
any of the following temperatures (in ºC): 100, 105, 110, or 115. That is, the poloxamer
may be heated to a temperature in the range of temperatures having an upper limit of 120,
115, 110, or 105 and an independently selected lower limit of 100, 105, 110, or 115,
wherein the lower limit is less than the upper limit. In some embodiments, the poloxamer is
heated to between about 100ºC and about 120°C for at least about 20 minutes, at least about
minutes, at least about 40 minutes, at least about 50 minutes, or at least about 60
minutes, at least about 70 minutes, at least about 80 minutes, or at least about 90 minutes.
In some embodiments, the poloxamer is heated to between about 100ºC and about 120°C
for at least about 98 minutes, at least about 100 minutes, at least about 110 minutes, at least
about 120 minutes, at least about 130 minutes, at least about 140 minutes, at least about 150
minutes, at least about 160 minutes, at least about 170 minutes, at least about 180 minutes,
at least about 190 minutes, at least about 200 minutes, at least about 210 minutes, at least
about 220 minutes, at least about 230 minutes, or at least about 240 minutes. In some
embodiments, the poloxamer is heated to between about 100ºC and about 120°C for less
than or equal to 250 minutes.
In some embodiments, the poloxamer (e.g., a purified poloxamer) is heated to
between about 80ºC and about 100°C. In some embodiments, the poloxamer is heated to a
temperature less than about any of the following temperatures (in ºC): 100, 95, 90, or 85. In
some embodiments, the poloxamer is heated to a temperature greater than about any of the
following temperatures (in ºC): 80, 85, 90, or 95. That is, the poloxamer may be heated to a
temperature in the range of temperatures having an upper limit of 100, 95, 90, or 85 and an
independently selected lower limit of 80, 85, 90, or 95, wherein the lower limit is less than
the upper limit. In some embodiments, the poloxamer is heated to between about 80ºC and
about 100°C for at least about 20 minutes, at least about 30 minutes, at least about 40
minutes, at least about 50 minutes, or at least about 60 minutes, at least about 70 minutes, at
least about 80 minutes, or at least about 90 minutes, at least about 100 minutes, at least
about 110 minutes, or at least about 120 minutes. In some embodiments, the poloxamer is
heated to between about 80ºC and about 100°C for at least about 122 minutes, at least about
130 minutes, at least about 140 minutes, at least about 150 minutes, at least about 160
minutes, at least about 170 minutes, at least about 180 minutes, at least about 190 minutes,
at least about 200 minutes, at least about 210 minutes, at least about 220 minutes, at least
about 230 minutes, or at least about 240 minutes. In some embodiments, the poloxamer is
heated to between about 80ºC and about 100°C for less than or equal to 250 minutes.
In some embodiments, the poloxamer (e.g., a purified poloxamer) is heated to
between about 60ºC and about 80°C. In some embodiments, the poloxamer is heated to a
temperature less than about any of the following temperatures (in ºC): 80, 75, 70, or 65. In
some embodiments, the poloxamer is heated to a temperature greater than about any of the
following temperatures (in ºC): 60, 65, 70, or 75. That is, the poloxamer may be heated to a
temperature in the range of temperatures having an upper limit of 80, 75, 70, or 65 and an
independently selected lower limit of 60, 65, 70, or 75, wherein the lower limit is less than
the upper limit. In some embodiments, the poloxamer is heated to between about 60ºC and
about 80°C for at least about 20 minutes, at least about 30 minutes, at least about 40
minutes, at least about 50 minutes, or at least about 60 minutes, at least about 70 minutes, at
least about 80 minutes, or at least about 90 minutes, at least about 100 minutes, at least
about 110 minutes, at least about 120 minutes, at least 130 minutes, or at least 140 minutes.
In some embodiments, the poloxamer is heated to between about 60ºC and about 80°C for
at least about 143 minutes, at least about 150 minutes, at least about 160 minutes, at least
about 170 minutes, at least about 180 minutes, at least about 190 minutes, at least about 200
minutes, at least about 210 minutes, at least about 220 minutes, at least about 230 minutes,
or at least about 240 minutes. In some embodiments, the poloxamer is heated to between
about 60ºC and about 80°C for less than or equal to 250 minutes.
In some embodiments, the poloxamer is heated under a vacuum. For example,
the poloxamer may be heated in a vacuum oven under an applied vacuum. As described
below, it was unexpectedly found that heating poloxamer at the temperatures described
herein under an applied vacuum results in improved poloxamer performance (see, e.g.,
Example 7). Stated another way, applying a vacuum to the poloxamer during heating does
not negate the beneficial effects of heating on subsequent poloxamer performance, e.g., in
cell culture.
In other embodiments, heating a poloxamer to a target temperature for a period
of time may refer to the time during which the poloxamer is at the particular temperature.
That is to say, time = 0 may indicate the time at which the poloxamer reached the target
temperature. For example, heating a poloxamer to 140ºC for 5 minutes may indicate that
the poloxamer was heated for 5 minutes after reaching a temperature of 140ºC. For
example, heating a poloxamer (e.g., a purified poloxamer) to between about 60ºC and about
185°C for at least 1 minute indicates that the poloxamer has achieved the target temperature
(e.g., between about 60ºC and about 185°C) for at least 1 minute.
In some embodiments, the temperature of the purified poloxamer during heating
process does not exceed about 120ºC. In some embodiments, the purified poloxamer may
be dissolved in a liquid or aqueous solution before the heating process. In some
embodiments, the purified poloxamer dissolved in a liquid or aqueous solution may be
heated to a higher temperature than would be used for a solid poloxamer. In some
embodiments, the purified poloxamer is a solid poloxamer before the heating process. In
some embodiments, the purified poloxamer is a liquid poloxamer at room temperature
before the heating process.
In some embodiments, the purified poloxamer is heated to a temperature of
about 80ºC to about 100ºC. In some embodiments, the purified poloxamer is heated to a
temperature of about 85ºC to about 91ºC. In some embodiments, the purified poloxamer is
heated to a temperature less than about any of the following temperatures (in ºC): 100, 99,
98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, or 81. In some
embodiments, the purified poloxamer is heated to a temperature greater than about any of
the following temperatures (in ºC): 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
95, 96, 97, 98, or 99. That is, the purified poloxamer may be heated to a temperature in the
range of temperatures having an upper limit of 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90,
89, 88, 87, 86, 85, 84, 83, 82, or 81 and an independently selected lower limit of 80, 81, 82,
83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99, wherein the lower limit is
less than the upper limit. In some embodiments, the purified poloxamer is heated to a
temperature of less than about 120ºC. In some embodiments, the purified poloxamer is
heated to a temperature of less than about any of 101ºC, 102ºC, 103ºC, 104ºC, 105ºC,
106ºC, 107ºC, 108ºC, 109ºC, 110ºC, 111ºC, 112ºC, 113ºC, 114ºC, 115ºC, 116ºC, 117ºC,
118ºC, and 119ºC.
The purified poloxamer may be heated for any desired period of time. In some
embodiments, the purified poloxamer is heated for about 10 to about 15 minutes. The
heating time may refer to the total time during which heat is applied to the poloxamer, so
the heating time is not limited to the time during which the poloxamer has achieved the
desired temperature. In some embodiments, the purified poloxamer is heated for a total
amount of time between about 10 and about 15 minutes, and the heating is stopped when
the poloxamer achieves a desired maximal temperature, e.g., about 80ºC to about 100ºC.
Any suitable heating apparatus known in the art may be used to heat the purified
poloxamer. As a non-limiting example, the solid poloxamer may be heated in a glass
container (e.g., a PYREX beaker, flask, or other open vessel) that is heated on a standard
laboratory heating plate (e.g., a stirring hotplate sold by Corning , Costar , or Thermo
Scientific ). Alternatively, the poloxamer may be heated in a vacuum oven.
Any suitable temperature measurement tool known in the art may be used to
measure the temperature of the poloxamer during/after heat treatment, provided that the
temperature measurement tool is used in such a way that an accurate measurement of
poloxamer temperature may be made (e.g., according to manufacturer’s instructions for
use). Non-limiting examples of suitable temperature measurement tools include without
limitation thermometers (e.g., liquid-in-glass thermometers), thermocouples (e.g., as
described below), resistance temperature detectors (RTDs), and/or thermistors. In some
embodiments, the temperature measurement tool may be intrinsic to the equipment used for
heating.
Cooling
In some embodiments, the methods of preparing a poloxamer for use in a cell
culture medium described herein include cooling a heated, purified poloxamer to form a
solid heat-treated poloxamer. In some embodiments, the liquid poloxamer is cooled to a
temperature below about 50ºC. The temperature to which the liquid poloxamer is cooled
may be any temperature below its freezing temperature, which may vary depending upon
the particular poloxamer used. For example, poloxamer 188 has a freezing temperature of
about 52ºC, so this poloxamer may be cooled to any temperature below about 52ºC to form
a solid heat-treated poloxamer.
The heated liquid poloxamer may be cooled at any temperature sufficient for the
poloxamer to freeze. In some embodiments, the heated liquid poloxamer is cooled at
ambient temperature. In some embodiments, the heated liquid poloxamer is cooled at about
2ºC to about 8ºC. In some embodiments, the heated liquid poloxamer is cooled at below
about 0ºC, e.g., at about -20ºC or at about -70ºC.
The heated liquid poloxamer may be cooled for any desired duration of time
sufficient for the heated liquid poloxamer to freeze at that cooling temperature. In some
embodiments, the liquid poloxamer is cooled for about 20 minutes. The cooling time may
depend on the temperature to which the poloxamer was heated and/or the cooling
temperature. Cooling temperatures and times may be empirically determined by observing
how long a liquid poloxamer (heated to a given temperature for a given amount of time)
takes to freeze at a particular cooling temperature.
Any suitable cooling apparatus known in the art, except for a prilling or milling
device, may be used to cool the heated liquid poloxamer. For example, the heated liquid
poloxamer may be placed in a refrigerator, freezer, or cold room maintained at a sufficient
cooling temperature as described above. Alternatively, no particular cooling apparatus may
be used, but instead the heated liquid poloxamer may be cooled in the heating apparatus
after the apparatus has been turned off or programmed to stop heating. In this case, the
heated liquid poloxamer is allowed to cool at ambient temperature. For example, if the
poloxamer is heated on a hotplate, the heated liquid poloxamer may be cooled simply by
leaving it on the hotplate after the hotplate’s heating function is turned off. Alternatively,
the poloxamer may be cooled in a vacuum oven. In some embodiments, cooling the heated
liquid poloxamer does not include using liquid nitrogen. In some embodiments, cooling the
heated liquid poloxamer does not include spraying or atomizing the heated liquid
poloxamer through a gas maintained at a specific temperature. In some embodiments,
cooling the heated liquid poloxamer does not include shaping the poloxamer into particles
or micro-particles of a specific or uniform size and/or shape.
Prilling/milling
In some embodiments, the cooling is not conducted in a prilling or milling
device. Poloxamer has been prepared in the art by prilling or milling to achieve a specific,
uniform poloxamer particle size and/or shape (for an example describing poloxamer prilling
and milling, see European Patent EP1661558 B1 or U.S. Patent No. 7,887,844). Poloxamer
prilling involves passing liquid poloxamer through an atomizer to create liquid poloxamer
particles and cooling these particles in a cooling medium, e.g., a gas maintained at a
specific temperature or liquid nitrogen. The temperature of the cooling medium is thought
to determine the freezing rate of the poloxamer, which influences the final size and shape of
the poloxamer particles. An example of a prilling device may include, without limitation, a
prilling tower. In a prilling tower, an atomized poloxamer is released from the top of the
tower, and it freezes into particles while falling through a gas or liquid cooling medium
(e.g., ambient air, air maintained at a specific temperature, or liquid nitrogen).
Poloxamer milling (or micro-milling) involves grinding a solid poloxamer, or
forcing a solid poloxamer by high pressure through a nozzle, until poloxamer particles of a
certain size are produced. Because milling may generate heat and poloxamers have a
relatively low melting temperature, the poloxamer is often cooled during the milling
process to maintain a solid phase, e.g., by chilling with cooled air or liquid nitrogen. The
poloxamer may also be cooled prior to milling and milled for a period of time insufficient
for the poloxamer to melt. Examples of milling devices may include without limitation air-
jet mills, ball-mills, and freezer mills (e.g., SPEX SamplePrep Freezer/Mill ).
Prilling and milling are useful for processes that require rigorous standards for
poloxamer particle size and shape, for example as part of drug formulations. Poloxamer is
known in the art as a component in drug formulations that aids solubility and affects drug
release. In these formulations, poloxamer particles must maintain standard characteristics
in order to impart the desired pharmacokinetic properties of the drug formulation and
adhere to rigorous drug safety and reproducibility standards. It is noted that the methods
described herein do not require such rigorous or precise standards for poloxamer, so these
prilling or milling methods are not used.
In some embodiments, the poloxamer has been treated by a prilling process
before it is heated as described herein. Many commercially available poloxamers for use in
cell culture (e.g., Pluronic F68 NF Prill Poloxamer 188 as sold by BASF ) have
undergone a prilling or micro-prilling process during manufacture. The heating and cooling
steps included in the methods described herein do not involve prilling. Rather, they may be
applied to poloxamer that has already been prilled or micro-prilled. It is a discovery of the
present disclosure that the performance of commercially available poloxamers (e.g., prilled
or micro-prilled poloxamer) in cell culture may be improved by heating and cooling as
described herein.
In some embodiments, the methods of preparing a poloxamer for use in a cell
culture medium described herein include adding a heat-treated poloxamer into a cell culture
medium. After heating and cooling, the solid heat-treated poloxamer may be dissolved in a
cell culture medium by any method known in the art. For example, if the poloxamer is
heated and cooled in an open glass vessel, the resulting solid heat-treated poloxamer may
simply be scraped or flaked off in an appropriate amount (by weight) to add to the cell
culture medium. The heat-treated poloxamer may be added to a cell culture medium
immediately, or it may be stored and added to a cell culture medium at a later time (e.g.,
more than about a day, more than about a month, or more than about a year after heat
treatment).
In some embodiments, the heating and cooling steps as described above are each
performed once before adding the heat-treated poloxamer into the cell culture medium. In
some embodiments, the heating and cooling steps as described above are repeated at least
once before adding the heat-treated poloxamer into the cell culture medium.
III. Poloxamers and Poloxamer Properties
Described herein are methods for preparing a poloxamer. In some
embodiments, the poloxamer produced by the methods is for use in a cell culture medium.
The term “poloxamer” may encompass many distinct compounds because
different lengths for the polyoxypropylene and polyoxyethylene chains may be used in
combination. The particular combination of polyoxypropylene and polyoxyethylene chains
present in a poloxamer may give rise to particular chemical and/or biophysical properties.
In some embodiments, the poloxamer has the chemical formula of
HO(C H O) (C H O) (C H O) H. In some embodiments, n (i.e., the polyoxyethylene
2 4 n 3 6 m 2 4 n
chain length) has a value from about 60 to about 150. In some embodiments, m (i.e., the
polyoxypropylene chain length) has a value from about 25 to about 60.
Poloxamers are often described by a numbering system that designates their
approximate molecular weight and percentage of polyoxyethylene content. These values
may refer to an average value in a poloxamer composition, rather than an absolute value of
each poloxamer molecule in the composition. Under this system, the first two digits are
multiplied by 100 to give the approximate molecular weight of the polyoxypropylene block,
and the third digit is multiplied by 10 to give the percentage by weight of the
polyoxyethylene block. For example, poloxamer 188 (CAS No. 90036) may refer to a
poloxamer with n having a value of about 80 and with m having a value of about 27 as in
the formula depicted above. Poloxamer 237 may refer to a poloxamer with n having a
value of about 64 and with m having a value of about 37. Poloxamer 338 may refer to a
poloxamer with n having a value of about 141 and with m having a value of about 44.
Poloxamer 407 may refer to a poloxamer with n having a value of about 101 and with m
having a value of about 56. In some embodiments, the poloxamer has an average molecular
weight of from about 6,000 to about 18,000 daltons. In some embodiments, poloxamer 188
may refer to a poloxamer with n having a value of about 80, with m having a value of about
27 as in the formula depicted above, and with the poloxamer having an average molecular
weight of from about 7680 to about 9510 g/mol. In some embodiments, poloxamer 188
may refer to a poloxamer with n having a value of about 80, with m having a value of about
27 as in the formula depicted above, and with the poloxamer having an average molecular
weight of from about 7000 to about 10000 g/mol.
Poloxamers sold under trade names, e.g., PLURONIC , may be named under a
different system. A letter may be used to indicate the physical state (e.g., F for solid, P for
paste, or L for liquid). A 2 or 3 digit number may be used to indicate the chemical
properties. The first one or two digits are multiplied by 300 to give the approximate
molecular weight of the polyoxypropylene block, and the third digit is multiplied by 10 to
give the percentage by weight of the polyoxyethylene block. For example, PLURONIC
F68 may refer to a solid poloxamer with n having a value of about 80 and with m having a
value of about 27 as in the formula depicted above. PLURONIC F87 may refer to a solid
poloxamer with n having a value of about 64 and with m having a value of about 37.
PLURONIC F108 may refer to a solid poloxamer with n having a value of about 141 and
with m having a value of about 44. PLURONIC F127 may refer to a solid poloxamer with
n having a value of about 101 and with m having a value of about 56.
Since poloxamers have both hydrophobic (polyoxypropylene) and hydrophilic
(polyoxyethylene) moieties of various lengths, different poloxamers may possess different
hydrophilic-lipophilic balances (HLBs). The HLB of a compound is determined by
calculating the relative proportion of the compound that is hydrophilic or lipophilic, and the
HLB value is used to predict the surfactant properties of a compound. For example, a
compound with an HLB less than 10 is predicted to be water insoluble, and a compound
with an HLB greater than 10 is predicted to be water soluble. In preferred embodiments,
the poloxamer for use in cell culture has an HLB of 24 or above. The HLB of a poloxamer
may be calculated according to methods well known in the art, including those described in
Griffin, W.C. (1954) J. Soc. Cosmet. Chemists 5(4):249-56 and Davies, J.T. (1957)
Gas/Liquid and Liquid/Liquid Interfaces: Proc. of 2 Intl. Congress Surface Activity,
Butterworths (London): 426-38.
In some embodiments, physical and/or chemical properties of a poloxamer may
be measured. For example, physical and/or chemical properties of a poloxamer may be
measured before and after heat-treatment as described herein to identify properties
associated with a heat-treated poloxamer. As another example, physical and/or chemical
properties of a good poloxamer lot and a bad poloxamer lot as described herein may be
measured to identify properties associated with a good poloxamer lot.
Examples of assays to measure physical and/or chemical properties may include,
without limitation, MALDI-MS, Gel Permeation Chromatography, Powder-XRD, Quasi-
elastic light scattering, and solid state NMR. MALDI-MS (Matrix-associated laser
desorption/ionization mass spectrometry) is known in the art as a technique for analyzing,
quantifying, or identifying a compound, e.g., by its molecular mass and charge. As a non-
limiting example, MALDI-MS may be used to identify a compound (e.g., an impurity)
preferentially associated with or present in a poloxamer lot before heat treatment or a bad
poloxamer lot, compared to a heat-treated poloxamer or a good poloxamer lot. Gel
Permeation Chromatography is known in the art as a technique for separating compounds
by size. As a non-limiting example, Gel Permeation Chromatography may be used to
isolate a compound (e.g., an impurity) preferentially associated with or present in a
poloxamer lot before heat treatment or a bad poloxamer lot, compared to a heat-treated
poloxamer or a good poloxamer lot. Powder-XRD (Powder X-ray Diffraction) is known in
the art as a technique for characterizing the structure a compound and may involve the steps
of generating a powder sample of a compound (containing a plurality of randomly oriented
crystallites) and using X-ray diffraction to analyze structural features of the crystallites. As
a non-limiting example, Powder-XRD may be used to characterize a structural property of a
heat-treated poloxamer or a good poloxamer lot, e.g., compared to a poloxamer before heat
treatment or a bad poloxamer lot. Quasi-elastic light scattering (a.k.a. dynamic light
scattering and photon correlation spectroscopy) is known in the art as a technique for
determining a size distribution profile of particles in a solution or suspension. As a non-
limiting example, Quasi-elastic light scattering may be used to identify a compound (e.g.,
an impurity) by its particle size that is preferentially associated with or present in a
poloxamer lot before heat treatment or a bad poloxamer lot, compared to a heat-treated
poloxamer or a good poloxamer lot.
Solid state NMR (nuclear magnetic resonance, or SSNMR) is known in the art
as a technique for determining a variety of structural features of a compound. For example,
solid state NMR may be used to characterize a molecular conformation, arrangement,
chemical shift, or polymorphic nature of a compound. As a non-limiting example, solid
state NMR may be used to characterize a structural property of a heat-treated poloxamer or
a good poloxamer lot, compared to a poloxamer before heat treatment or a bad poloxamer
lot. In some embodiments, a structural property determined by solid state NMR may
include the ratio of crystalline to amorphous poloxamer in a poloxamer sample. As another
non-limiting example, solid state NMR may be used to provide spectra that can resolve or
profile one or more poloxamer polymorphs. In some embodiments, solid state NMR may
be used to resolve one or more poloxamer polymorphs in a good poloxamer lot or a heat-
treated poloxamer, as compared to the poloxamer polymorphs present in a bad poloxamer
lot or a poloxamer before heat treatment. In some embodiments, a poloxamer spectrum
generated by solid state NMR may be correlated with the performance of a poloxamer in a
cell culture medium, e.g., by measuring the cell viability of a cell culture grown in a cell
culture medium containing a good poloxamer lot or a heat-treated poloxamer, as compared
to the cell viability of a cell culture grown in a cell culture medium containing a bad
poloxamer lot or a poloxamer before heat treatment.
IV. Use of Poloxamers in Cell Culture and Production of Polypeptides
Heat-treated poloxamers described herein may find use in methods (e.g., of
culturing cells and producing polypeptides using a culture medium containing a heat-treated
poloxamer of the present disclosure) and in compositions (e.g., a cell culture medium
containing a heat-treated poloxamer of the present disclosure).
Use of poloxamer in cell culture
Poloxamers can be used as additives to cell culture media known in the art.
Without wishing to be bound to theory, it is thought that poloxamers have many functions
in cell culture media that may protect cells from damage and enhance cell viability. For
example, poloxamer may act as a shear protectant to cells. Poloxamer may reduce cell-
bubble attachment and/or reduce shock when bubbles burst, thereby preventing cell
damage. Poloxamer may also alter bubble velocity and frequency, improve cell drainage
from the foam layer, and/or strengthen cell membranes. See, e.g., Meier, S.J., et al. (1999)
Biotechnol. Bioeng. 62(4):468-78; Chisti, Y. (2000) Trends Biotechnol. 18(10):420-32; and
Tharmalingam, T., et al. (2008) Mol. Biotechnol. 39(2): 167-77.
Heat-treated poloxamer as described herein may be added to a cell culture
medium at any concentration typically used for poloxamer. In some embodiments, the cell
culture medium includes the heat-treated poloxamer at about 0.1 g/L to about 10 g/L. In
some embodiments, the cell culture medium includes the heat-treated poloxamer at about
0.1 g/L to about 3 g/L. In some embodiments, the cell culture medium includes the heat-
treated poloxamer at about 3 g/L to about 10 g/L. In some embodiments, the cell culture
medium includes the heat-treated poloxamer at about 0.1 g/L, at about 0.2 g/L, at about 0.3
g/L, at about 0.4 g/L, at about 0.5 g/L, at about 0.6 g/L, at about 0.7 g/L, at about 0.8 g/L, at
about 0.9 g/L, at about 1 g/L, at about 2 g/L, at about 3 g/L, at about 4 g/L, at about 5 g/L,
at about 6 g/L, at about 7 g/L, at about 8 g/L, at about 9 g/L, or at about 10 g/L. In some
embodiments, a heat-treated poloxamer prepared as described herein may be used at a
lower concentration in a cell culture medium to achieve a desired level of cell viability than
a poloxamer before heat treatment. In some embodiments, a heat-treated poloxamer
prepared as described herein may be used at a more consistent or standardized
concentration in a cell culture medium to achieve a desired level of cell viability than a
poloxamer before heat treatment.
Surfactants such as poloxamers have a limit in solution, termed the critical
micelle concentration (CMC), beyond which additional surfactant molecules added begin to
be incorporated into micelles, rather than dissolving into the solution. At concentrations
higher than the CMC, the surface tension of the solution no longer decreases at the same
rate proportional to the concentration of surfactant. In preferred embodiments, the heat-
treated poloxamer is added to a cell culture medium at a concentration lower than its CMC.
For example, the CMC of poloxamer 188 has been determined to be 100 mg/mL (Kabanov,
A.V., et al. (1995) Macromolecules 28(7):2303-14). The CMC of a poloxamer may be
determined by measuring the surface tension of a solution while the poloxamer is added.
The concentration at which increasing the poloxamer concentration no longer results in
increased surface tension is the CMC for that poloxamer. Surface tension may be
measured, for example and without limitation, using a tensiometer (e.g., Sigma 700/701
tensiometer from Attension).
Cell culture media
Certain aspects of the present disclosure relate to culturing a cell in a cell culture
medium. Any cell culture medium known in the art, suitable for the desired type of cell
and/or polypeptide product, may be used. In some embodiments, the cell culture medium is
a chemically defined medium. In other embodiments, the cell culture medium is a
chemically undefined medium. In some embodiments, a heat-treated poloxamer as
described herein is added to a basal cell culture medium. In some embodiments, a heat-
treated poloxamer as described herein is added to a feed or batch-feed cell culture medium.
Commercially available media may be used, including such as, but not limited
to, Ham's F10 (Sigma), Minimal Essential Medium ([MEM], Sigma), RPMI-1640 (Sigma),
Dulbecco's Modified Eagle's Medium ([DMEM], Sigma), Luria broth (LB), and Terrific
broth (TB), and any of these media may be supplemented with any of the media
components as detailed herein (e.g., a heat-treated poloxamer). In addition, any of the
media described in Ham and Wallace, Meth. Enz., 58:44 (1979), Barnes and Sato, Anal.
Biochem., 102:255 (1980), Vijayasankaran et al., Biomacromolecules., 6:605:611 (2005),
Patkar et al., J Biotechnology, 93:217-229 (2002), U.S. Pat. Nos. 4,767,704; 4,657,866;
4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; U.S. Pat. No. Re. 30,985; or U.S.
Pat. No. 5,122,469, the disclosures of all of which are incorporated herein by reference in
their entirety, may be supplemented with any of the media components as detailed herein
(e.g., a heat-treated poloxamer).
Any media described herein may also be supplemented as necessary with
hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth
factor), ions (such as sodium, chloride, calcium, magnesium, and phosphate), buffers (such
as HEPES), nucleosides (such as adenosine and thymidine), trace elements (defined as
inorganic compounds usually present at final concentrations in the micromolar range),
surfactants such as poloxamer, and glucose or an equivalent energy source. In some
embodiments, a cell culture medium described herein contains proteins derived from a plant
or an animal. In some embodiments, a cell culture provided herein is free of proteins
derived from a plant or an animal. Any other necessary supplements may also be included
at appropriate concentrations that would be known to those skilled in the art.
Cell viability
In some embodiments, cell viability in a cell culture medium including the heat-
treated poloxamer is increased as compared to cell viability in a cell culture medium
including untreated poloxamer (or poloxamer before heat treatment). It is a discovery of
the present disclosure that preparation of a poloxamer as described herein results in
increased cell viability when the heat-treated poloxamer is used in a cell culture medium, as
compared when untreated poloxamer is used in the same cell culture medium. Methods for
testing cell viability are known in the art. In some embodiments, cell viability is measured
as described in detail in the Examples provided herein. In some embodiments, cell viability
in a cell culture medium may be measured after about 1 hour, after about 2 hours, or after
about 3 hours (e.g., as described below).
As used herein, cell viability is quantified as the percentage of living cells in a
solution (i.e., the number of live cells divided by the total number of cells). Any suitable
method known in the art may be used to measure cell viability. As cells are either live or
dead, cell viability may be determined by quantifying either dead cells or live cells. One
suitable method is trypan blue exclusion. In this method, a sample of cells is obtained from
a cell culture. A solution of trypan blue is added to the sample. Only non-viable cells take
up trypan blue, and these are subsequently stained blue. Therefore, the number of blue cells
is counted, subtracted by the total number of cells to yield the number of live cells, and this
number is divided by the total number of cells to yield cell viability. Cells may be counted
manually, as with a hemacytometer, or automatically, as with, e.g., a Vi-Cell viability
analyzer (Beckman Coulter). Other assays for determining cell viability may include,
without limitation, propidium iodide staining, TUNEL, Resazurin, methyl violet, lactate
dehydrogenase, fluorescein diacetate hydrolysis, MTT, caspase, and ATP assays.
The effect of a heat-treated poloxamer may be determined, for example, by
measuring the cell viability in a cell culture grown in a cell culture medium containing the
heat-treated poloxamer and comparing it to the cell viability in a cell culture grown in a cell
culture medium containing the same concentration of untreated poloxamer. In some
embodiments, a cell culture may be grown in a baffled shake flask. In some embodiments,
the use of a heat-treated poloxamer, compared to an untreated poloxamer, increases the cell
viability by at least about 10%. In some embodiments, the use of a heat-treated poloxamer,
compared to an untreated poloxamer, increases the cell viability by at least about 15%. In
some embodiments, the use of a heat-treated poloxamer, compared to an untreated
poloxamer, increases the cell viability by at least about 20%. In some embodiments, the
use of a heat-treated poloxamer, compared to an untreated poloxamer, increases the cell
viability by at least about 25%. In some embodiments, the use of a heat-treated poloxamer,
compared to an untreated poloxamer, increases the cell viability by at least about 30%. In
some embodiments, the use of a heat-treated poloxamer, compared to an untreated
poloxamer, increases the cell viability by at least about 35%. In some embodiments, the
use of a heat-treated poloxamer, compared to an untreated poloxamer, increases the cell
viability by at least about 40%. In some embodiments, the use of a heat-treated poloxamer,
compared to an untreated poloxamer, increases the cell viability by at least about 45%. In
some embodiments, the use of a heat-treated poloxamer, compared to an untreated
poloxamer, increases the cell viability by at least about 50%.
In some embodiments, cell viability in a cell culture medium comprising a heat-
treated poloxamer of the present disclosure is increased by at least 10% as compared to cell
viability in a cell culture medium comprising the poloxamer before heat treatment. In some
embodiments, the cell viability is increased by at least about 1%, at least about 2%, at least
about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least
about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at
least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about
17%, at least about 18%, at least about 19%, at least about 20%, at least about 21%, at least
about 22%, at least about 23%, at least about 24%, at least about 25%, at least about 26%,
at least about 27%, at least about 28%, at least about 29%, at least about 30%, at least about
31%, at least about 32%, at least about 33%, at least about 34%, at least about 35%, at least
about 36%, at least about 37%, at least about 38%, at least about 39%, or at least about
40%.
Heat-treated poloxamer may be especially useful for improving the performance
of a poloxamer (e.g., a particular lot of a desired poloxamer) that does not yield satisfactory
cell viability when added to a cell culture medium. In some embodiments, cell viability in a
cell culture medium with untreated poloxamer is below about 80%. In some embodiments,
cell viability in a cell culture medium with untreated poloxamer is below about 70%. In
some embodiments, cell viability in a cell culture medium with untreated poloxamer is
below about 60%. In some embodiments, cell viability in a cell culture medium with
untreated poloxamer is below about 50%. In some embodiments, cell viability in a cell
culture medium with untreated poloxamer is below about 40%.
Cell Growth and Polypeptide Production
In some embodiments, a cell of the present disclosure (e.g., a cell cultured in a
cell culture medium described herein) may contain a polynucleotide of interest (e.g., a
polynucleotide encoding a polypeptide of interest, or a polynucleotide of interest per se). In
some embodiments, a cell of the present disclosure may be transfected, transformed, or
otherwise genetically modified to include a polynucleotide of interest. Methods suitable for
transfecting or transforming a variety of cells are widely known in the art. Exemplary
references are provided below with respect to polypeptide production; one of skill in the art
will appreciate that the methods disclosed therein are not limited to polypeptide production.
Generally the cells are combined (contacted) with any of the cell culture media
described herein under one or more conditions that promote any of cell growth, maintenance
and/or polynucleotide and/or polypeptide production. Methods of culturing a cell and
producing a polypeptide employ a culturing vessel (bioreactor) to contain the cell and cell
culture medium. The culturing vessel can be composed of any material that is suitable for
culturing cells, including glass, plastic or metal. Typically, the culturing vessel will be at least
1 liter and may be 10, 100, 250, 500, 1000, 2500, 5000, 8000, 10,000, 25,000 liters or more.
The culture conditions, such as temperature, pH, and the like, are those previously used with
the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
Culturing conditions that may be adjusted during the culturing process include but are not
limited to pH and temperature.
A cell culture may be maintained under conditions conducive to the survival,
growth, viability (maintenance), and polypeptide production capabilities of the cell culture.
The precise conditions will vary depending on the cell type, the organism from which the cell
was derived, and the nature and character of the expressed polypeptide. During the
polypeptide production phase, the cell culture may optionally be maintained under a second
set of culture conditions (as compared to the initial growth phase) conducive to the survival
and viability of the cell culture and appropriate for expression of the desired polypeptide.
In certain cases, it may be beneficial or necessary to supplement the cell culture
with nutrients or other medium components that have been depleted or metabolized by the
cells. For example, it might be advantageous to supplement the cell culture with nutrients or
other medium components observed to have been depleted during monitoring of the cell
culture. Alternatively or additionally, it may be beneficial or necessary to supplement the cell
culture prior to the production phase. As non-limiting examples, it may be beneficial or
necessary to supplement the cell culture with hormones and/or other growth factors,
particular ions (such as sodium, chloride, calcium, magnesium, and phosphate), buffers,
vitamins, nucleosides or nucleotides, trace elements (inorganic compounds usually present at
very low final concentrations), amino acids, lipids, or glucose or other energy source.
The cell culture media detailed herein can be used in a method of culturing cells to
produce polypeptides, including antibodies. The medium may be used in a method of
culturing cells, whether by batch culture, fed batch culture or perfusion culture, and can be
used in a method of producing any polypeptide including any embodiments of the
polypeptide as described herein. The polypeptides produced by the methods detailed herein
(e.g., of culturing cells and producing polypeptides using a culture medium containing a heat-
treated poloxamer of the present disclosure) may be homologous to the host cell, or
preferably, may be exogenous, meaning that they are heterologous, i.e., foreign, to the host
cell being utilized, such as a human protein produced by a CHO cell, or a yeast polypeptide
produced by a mammalian cell. In one variation, the polypeptide is a mammalian polypeptide
(such as an antibody) directly secreted into the medium by the host cell. In another variation,
the polypeptide is released into the medium by lysis of a cell comprising a polynucleotide
encoding the polypeptide.
Any polypeptide that is expressible in a host cell may be produced in accordance
with the present disclosure and may be present in the described compositions. The
polypeptide may be expressed from a gene that is endogenous to the host cell, or from a gene
that is introduced into the host cell through genetic engineering. The polypeptide may be one
that occurs in nature, or may alternatively have a sequence that was engineered or selected by
the hand of man. An engineered polypeptide may be assembled from other polypeptide
segments that individually occur in nature, or may include one or more segments that are not
naturally occurring.
Polypeptides that may desirably be expressed in accordance with the present
invention will often be selected on the basis of an interesting biological or chemical activity.
For example, the present invention may be employed to express any pharmaceutically or
commercially relevant enzyme, receptor, antibody, hormone, regulatory factor, antigen,
binding agent, etc.
Methods for producing polypeptides, such as antibodies, in cell culture are well
known in the art. Described herein are non-limiting exemplary methods for producing an
antibody (e.g., full length antibodies, antibody fragments and multispecific antibodies) in cell
culture. The methods herein can be adapted by one of skill in the art for the production of
other proteins, such as protein-based inhibitors. See Molecular Cloning: A Laboratory
Manual (Sambrook et al., 4 ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
N.Y., 2012); Current Protocols in Molecular Biology (F.M. Ausubel, et al. eds., 2003); Short
Protocols in Molecular Biology (Ausubel et al., eds., J. Wiley and Sons, 2002); Current
Protocols in Protein Science, (Horswill et al., 2006); Antibodies, A Laboratory Manual
(Harlow and Lane, eds., 1988); Culture of Animal Cells: A Manual of Basic Technique and
Specialized Applications (R.I. Freshney, 6 ed., J. Wiley and Sons, 2010) for generally well
understood and commonly employed techniques and procedures for the production of
proteins (e.g., therapeutic proteins), which are all incorporated herein by reference in their
entirety.
Conditions suitable for the production of polypeptides are known in the art for a
variety of host cell types and polypeptides. The culture conditions, such as temperature, pH,
and the like, are those previously used with the host cell selected for expression, and will be
apparent to the ordinarily skilled artisan.
A cell culture may be agitated or shaken during cell culture in order to increase
oxygenation and dispersion of nutrients to the cells. The use of poloxamer may be
particularly advantageous in cell cultures that are agitated because of the shear forces that
potentially harm the cells. In accordance with the present invention, one of ordinary skill in
the art will understand that it can be beneficial to control or regulate certain internal
conditions of the bioreactor during the initial growth phase, including but not limited to pH,
temperature, oxygenation, etc. For example, pH can be controlled by supplying an
appropriate amount of acid or base and oxygenation can be controlled with sparging devices
that are well known in the art.
Cells
Suitable cells for culturing in a culture medium and producing a polypeptide may
include prokaryotic, yeast, or higher eukaryotic (e.g., mammalian) cells. In some
embodiments, a mammalian cell is used. In some embodiments, a Chinese Hamster Ovary
(CHO) cell is used.
Mammalian cells may be cultured, and propagation of mammalian cells in culture
(tissue culture) has become a routine procedure. Examples of mammalian host cell lines may
include, without limitation, monkey kidney CV1 line transformed by SV40 (COS-7, ATCC
CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in
suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells
(BHK, ATCC CCL 10); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251 (1980));
monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76,
ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney
cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human
lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary
tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci.
383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (Hep G2). Other
useful mammalian host cell lines include myeloma cell lines such as NS0 and Sp2/0. For a
review of certain mammalian host cell lines suitable for antibody production, see, e.g.,
Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press,
Totowa, N.J., 2003), pp. 255-268.
In some embodiments, CHO cells may be cultured. CHO cells are well known
and routinely used in the art for producing polypeptides in cell culture, for example
antibodies. CHO cells may include, but are not limited to, DHFR CHO cells (Urlaub et al.,
Proc. Natl. Acad. Sci. USA 77:4216 (1980)), e.g., ATCC CRL-9096.
Suitable prokaryotic cells for this purpose include eubacteria, such as Gram-
negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia,
e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella
typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B.
subtilis and B. licheniformis (e.g., B. licheniformis 41P disclosed in DD 266,710 published 12
Apr. 1989), Pseudomonas such as P. aeruginosa, and Streptomyces. One preferred E. coli
cloning host is E. coli 294 (ATCC 31,446), although other strains such as E. coli B, E. coli
X1776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325) are suitable. These examples are
illustrative rather than limiting.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast
are suitable cloning or expression hosts for antibody-encoding vectors. Saccharomyces
cerevisiae, or common baker’s yeast, is the most commonly used among lower eukaryotic
host microorganisms. However, a number of other genera, species, and strains are commonly
available and useful herein, such as Schizosaccharomyces pombe; Kluyveromyces hosts such
as, e.g., K. lactis, K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii
(ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K.
thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070);
Candida; Trichoderma reesia (EP 244,234); Neurospora crassa; Schwanniomyces such as
Schwanniomyces occidentalis; and filamentous fungi such as, e.g., Neurospora, Penicillium,
Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger. For a review
discussing the use of yeasts and filamentous fungi for the production of therapeutic proteins,
see, e.g., Gerngross, Nat. Biotech. 22:1409-1414 (2004).
Certain fungi and yeast strains may be selected in which glycosylation pathways
have been “humanized,” resulting in the production of an antibody with a partially or fully
human glycosylation pattern. See, e.g., Li et al., Nat. Biotech. 24:210-215 (2006) (describing
humanization of the glycosylation pathway in Pichia pastoris); and Gerngross et al., supra.
Suitable host cells for the expression of glycosylated antibody are also derived
from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells
include plant and insect cells. Numerous baculoviral strains and variants and insect cells from
hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus
(mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori have been identified. A
variety of viral strains for transfection are publicly available, e.g., the L-1 variant of
Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses
may be used as the virus herein according to the description, particularly for transfection of
Spodoptera frugiperda cells. Examples of insect cells may include, without limitation,
Drosophila cells (e.g., S2 cells), Trichoplusia ni cells (e.g., High Five cells), and
Spodoptera frugiperda cells (e.g., Sf21 or Sf9 cells).
Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, duckweed
(Leninaceae), alfalfa (M. truncatula), and tobacco can also be utilized as hosts. See, e.g., U.S.
Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing
PLANTIBODIES technology for producing antibodies in transgenic plants).
Antibody production
In some embodiments, the cell cultured in a cell culture medium containing a
heat-treated poloxamer is used to produce an antibody.
In some embodiments, the antibody is a monoclonal antibody. The modifier
“monoclonal” indicates the character of the antibody as being obtained from a substantially
homogeneous population of antibodies, and is not to be construed as requiring production of
the antibody by any particular method. For example, the monoclonal antibodies to be used in
accordance with the invention may be made by a variety of techniques, including, for
example, the hybridoma method (e.g., Kohler and Milstein, Nature, 256:495-97 (1975);
Hongo et al., Hybridoma, 14 (3): 253-260 (1995), Harlow et al., Antibodies: A Laboratory
Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling et al., in:
Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981)),
recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567), phage-display technologies
(see, e.g., Clackson et al., Nature, 352: 624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-
597 (1992); Sidhu et al., J. Mol. Biol. 338(2): 299-310 (2004); Lee et al., J. Mol. Biol.
340(5): 1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472
(2004); and Lee et al., J. Immunol. Methods 284(1-2): 119-132 (2004), and technologies for
producing human or human-like antibodies in animals that have parts or all of the human
immunoglobulin loci or genes encoding human immunoglobulin sequences (see, e.g., WO
1998/24893; ; ; ; Jakobovits et al., Proc.
Natl. Acad. Sci. USA 90: 2551 (1993); Jakobovits et al., Nature 362: 255-258 (1993);
Bruggemann et al., Year in Immunol. 7:33 (1993); U.S. Pat. Nos. 5,545,807; 5,545,806;
,569,825; 5,625,126; 5,633,425; and 5,661,016; Marks et al., Bio/Technology 10: 779-783
(1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368: 812-813 (1994);
Fishwild et al., Nature Biotechnol. 14: 845-851 (1996); Neuberger, Nature Biotechnol. 14:
826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13: 65-93 (1995). In some
embodiments, the antibody produced by the methods described herein is a humanized
antibody, a chimeric antibody, a human antibody, a library-derived antibody, or a
multispecific antibody.
Antibodies may be produced using recombinant methods, for example in the
production of an antibody using CHO cells. For recombinant production of an anti-antigen
antibody, nucleic acid encoding the antibody is isolated and inserted into a replicable vector
for further cloning (amplification of the DNA) or for expression. DNA encoding the antibody
may be readily isolated and sequenced using conventional procedures (e.g., by using
oligonucleotide probes that are capable of binding specifically to genes encoding the heavy
and light chains of the antibody). Many vectors are available. The vector components
generally include, but are not limited to, one or more of the following: a signal sequence, an
origin of replication, one or more marker genes, an enhancer element, a promoter, and a
transcription termination sequence.
An antibody of the description may be produced recombinantly not only directly,
but also as a fusion polypeptide with a heterologous polypeptide, which is preferably a signal
sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature
protein or polypeptide. The heterologous signal sequence selected preferably is one that is
recognized and processed (e.g., cleaved by a signal peptidase) by the host cell. For
prokaryotic host cells that do not recognize and process a native antibody signal sequence,
the signal sequence is substituted by a prokaryotic signal sequence selected, for example,
from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II
leaders. For yeast secretion the native signal sequence may be substituted by, e.g., the yeast
invertase leader, a factor leader (including Saccharomyces and Kluyveromyces α-factor
leaders), or acid phosphatase leader, the C. albicans glucoamylase leader, or the signal
described in WO 90/13646. In mammalian cell expression, mammalian signal sequences as
well as viral secretory leaders, for example, the herpes simplex gD signal, are available.
The antibody can be produced intracellularly, in the periplasmic space, or directly
secreted into the medium. If the antibody is produced intracellularly, as a first step, the
particulate debris, either host cells or lysed fragments, are removed, for example, by
centrifugation or ultrafiltration. Carter et al., Bio/Technology 10:163-167 (1992) describe a
procedure for isolating antibodies which are secreted to the periplasmic space of E. coli.
Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and
phenylmethylsulfonylfluoride (PMSF) over about 30 min. Cell debris can be removed by
centrifugation. Where the antibody is secreted into the medium, supernatants from such
expression systems are generally first concentrated using a commercially available protein
concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A
protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit
proteolysis and antibiotics may be included to prevent the growth of adventitious
contaminants.
Antibodies can be purified using, for example, hydroxylapatite chromatography,
hydrophobic interaction chromatography, gel electrophoresis, dialysis, and affinity
chromatography, with affinity chromatography being among one of the typically preferred
purification steps. The suitability of protein A as an affinity ligand depends on the species
and isotype of any immunoglobulin Fc domain that is present in the antibody. Protein A can
be used to purify antibodies that are based on human γ1, γ2, or γ4 heavy chains (Lindmark et
al., J. Immunol. Meth. 62:1-13 (1983)). Protein G is recommended for all mouse isotypes and
for human γ3 (Guss et al., EMBO J. 5:15671575 (1986)). The matrix to which the affinity
ligand is attached is most often agarose, but other matrices are available. Mechanically stable
matrices such as controlled pore glass or poly(styrenedivinyl)benzene allow for faster flow
rates and shorter processing times than can be achieved with agarose. Where the antibody
comprises a C 3 domain, the Bakerbond ABX resin (J. T. Baker, Phillipsburg, N.J.) is
useful for purification. Other techniques for protein purification such as fractionation on an
ion-exchange column, ethanol precipitation, Reverse Phase HPLC, chromatography on silica,
chromatography on heparin SEPHAROSE chromatography on an anion or cation exchange
resin (such as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium
sulfate precipitation are also available depending on the antibody to be recovered.
In some embodiments, the antibody described herein is an antigen-binding
fragment thereof. Examples of antigen-binding fragment include Fab, Fab', F(ab') , and Fv
fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific
antibodies formed from antibody fragments. The Fab fragment contains the heavy- and light-
chain variable domains and also contains the constant domain of the light chain and the first
constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the
addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including
one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for
Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')
antibody fragments originally were produced as pairs of Fab' fragments which have hinge
cysteines between them. Other chemical couplings of antibody fragments are also known.
“Fv” is the minimum antibody fragment which contains a complete antigen-binding site.
“Single-chain Fv” or “scFv” antibody fragments comprise the VH and VL domains of
antibody, wherein these domains are present in a single polypeptide chain. Generally, the
scFv polypeptide further comprises a polypeptide linker between the VH and VL domains
which enables the scFv to form the desired structure for antigen binding. For a review of
scFv, see, e.g., Pluckthün, in The Pharmacology of Monoclonal Antibodies, vol. 113,
Rosenburg and Moore eds., (Springer-Verlag, New York, 1994), pp. 269-315. Many of the
methods for purifying an antibody described above may be suitably adapted for purifying an
antigen-binding antibody fragment.
In general, various methodologies for preparing antibodies for use in research,
testing, and clinical are well-established in the art, consistent with the above-described
methodologies and/or as deemed appropriate by one skilled in the art for a particular antibody
of interest.
EXAMPLES
The invention will be more fully understood by reference to the following
examples. The examples should not, however, be construed as limiting the scope of the
invention. It is understood that the examples and embodiments described herein are for
illustrative purposes only and that various modifications or changes in light thereof will be
suggested to persons skilled in the art and are to be included within the spirit and purview of
this application and scope of the appended claims.
Example 1: Heat treatment improves poloxamer performance for cell culture
Poloxamer is commonly used in cell culture as a surfactant that protects cells from
sparging and/or bubble-related damage. Unfortunately, lot-to-lot variability undermines its
effectiveness and results in reductions in recombinant product yield. For example, a bad lot
of poloxamer reduces cell viability and may cause a decrease in product titer of up to 45%.
After an extensive series of investigations, it was found that bad poloxamer lots were the
source of significant reductions in product yield and subsequent financial losses in industrial
protein production. Therefore, methods to improve poloxamer performance would be highly
beneficial.
Surprisingly, it has been found that a single heat treatment is able to increase
poloxamer performance in cell culture. Importantly, this heat treatment not only improves
the performance of bad poloxamer lots, but it is also able to further enhance the performance
of good lots as well. Describe herein are methods for treating poloxamer to improve its
performance as a cell culture supplement.
Methods
Poloxamer treatment
15g of poloxamer 188 (PLURONIC F 68 NF Prill Poloxamer 188, BASF) were
heated on a standard stir plate for 10-12 minutes. Heating was stopped when the poloxamer
reached a temperature of 86-91ºC. Poloxamer was then cooled at room temperature, 2-8ºC,
or -72ºC for approximately 20 minutes. Solid poloxamer was then flaked off and added to
cell culture medium for testing.
Cell culture testing model
Poloxamer 188, heat treated as described above, was added to standard, serum-
free, CHO cell medium at a final concentration of 1g/L. CHO cells were grown at 37ºC in
-75 mL cell culture medium in 250 mL baffled shake flasks at a concentration of 1.5x10
cells/mL in 5% CO . During cell culture, flasks were rotated on an orbital shaker between
250 and 350 rpm. The use baffled shake flasks created a large amount of entrained bubbles
in the cultures. Cell viability was measured by trypan blue exclusion using a Vi-Cell
viability analyzer (Beckman Coulter). 300 µL of cell culture was sampled, and the
percentage of cell viability was calculated by dividing the number of viable cells (i.e., those
that did not take up trypan blue) by the total number of cells in the sample.
Results
A simple screening model was developed for simulating the effect of poloxamer
on cell culture viability at a laboratory, rather than industrial, scale. Briefly, CHO cells were
grown in 250 mL flasks as described above. In order to maximize the difference in cell
viability produced by good and bad lots of poloxamer, volume of cell culture medium and
shaking speed were tested. Cells were grown in 25, 50, or 75 mL medium and shaken on an
orbital shaker platform at 250, 300, or 350 rpm. It was found that the volume of medium had
no effect on Δ (i.e., the difference in cell viability, as a percentage, between a known
viability
good lot and a known bad lot of poloxamer), but higher shaking speeds showed an increase in
viability
As shown in it was found that heat-treating poloxamer (see Methods)
significantly improves the performance of poloxamer in cell culture. A variety of poloxamer
lots were tested for their effect on cell viability using the above screening model. Some lots
were known to perform well, and others were suspected to be poorly performing. For each
lot, untreated and heat-treated (HT) batches were added to the cell culture medium for testing.
Compared to untreated poloxamer, heat-treated poloxamer was found to improve cell
viability in all lots tested (. In some cases, heat-treated poloxamer was able to double
viability, from 45% to nearly 90%. Importantly, heat-treated poloxamer was able to improve
viability for lots that already demonstrated high performance (see, e.g., “Good 4” in .
These results demonstrate that heat treatment of poloxamer is able to improve its
effect on viability in cell culture. Heat treatment is able to dramatically improve the
performance of bad poloxamer lots and even further enhance the performance of good lots,
suggesting implementation of poloxamer heat treatment may significantly reduce the problem
of poloxamer lot variability.
Example 2: Poloxamer heat treatment measured with an RTD thermometer
The experiments described in Example 1 were conducted on a hot plate. These
experiments involved heating poloxamer to approximately 80-100°C (measured by RTD)
over the course of 10 minutes. These experiments were repeated with the addition of a sample
heated to above 100ºC (i.e., 124ºC).
Methods
Poloxamer 188 Manufacturers and Lots
Poloxamer 188 material was used. Identifiers and associated cell culture
performance (determined by performance in the High Shear Shake Flask Test, HSSF) are
listed in Table 1.
Table 1. Identifiers (used to refer to lot throughout the subsequent examples) and associated
cell culture performance from HSSF data.
Identifier Cell Culture Performance
G Bad
D Good
H Bad
B Bad
C Bad
F Bad
E Marginal
A Good
Heat Treatment Methods
To evaluate the poloxamer heat treatment process, several methods of heat
treatment were evaluated: heating on a hot plate, in an oven, or in an autoclave.
Hot Plate
Five to fifteen grams of poloxamer was placed in a glass beaker (100-400mL) and
heated on a hot plate with continuous stirring. Temperature of the poloxamer was measured
using a thermocouple (Kaye 731 Thermocouple) or a resistance temperature detector (RTD)
(Fluke 5627A-12 Precision RTD Probe). Poloxamer was heated until it reached the target
temperature (approximately five to ten minutes) and then was immediately removed from
heat. The molten poloxamer was allowed to cool at room temperature.
Oven
Five grams of poloxamer was weighed out in a 20 mL scintillation glass vial. A
thermocouple was secured in the vial such that the tip was immersed in the dry poloxamer.
The poloxamer and thermocouple were then placed in an oven (Yamato ADP 21 Vacuum
Drying Oven) already at the target temperature. Unless otherwise specified, ovens were
operated without the vacuum function (at atmospheric pressure). The poloxamer was allowed
to reach target temperature (+/- 3°C as measured by the thermocouple), and the time at which
the poloxamer reached this target temperature was marked as time = 0. After the desired
incubation time, a slight vacuum was applied for 10-30 seconds to siphon off any volatiles
released into the oven. After venting, the glass vial was removed from the oven and allowed
to cool at room temperature (uncapped).
CHO Cell Culture and Media
Standard, serum-free, CHO cell medium was used for all experiments, with one
notable exception: Pluronic F68 was omitted from the medium. To support this study, two
CHO cell line thaws were maintained in a seed train bioreactor (STB).
High Shear Cell Culture Shake Flask Method
Addition of poloxamer samples to cell culture media
Media was prepared by aliquoting 250 mL of standard, serum-free, CHO cell
medium (without poloxamer) per sample into PETG containers and adding 0.25 grams of
poloxamer sample to each aliquot. Media was agitated for at least 5 minutes at 150 rpm in
order to thoroughly dissolve poloxamer in media. Media was then vacuum-filtered in a
biosafety cabinet (BSC) using 0.22 µm PES filter units. Media was stored at 37°C for use
within 24 hours.
Media exchange and cell culture assay
Cell culture samples were transferred into 50 mL Falcon tubes such that each
aliquot contained approximately 7.5 x 10E7 cells. The cells were centrifuged for 10 minutes
at 830 x g to form a pellet. The supernatant was removed and cells were re-suspended in
media containing poloxamer samples to test, and then transferred into 250 mL vented baffled
shake flasks. The initial total cell density (TCD) and viability were measured using a NOVA
Flex after shaking flasks at 150 rpm for a few minutes to evenly distribute cells. Shake flasks
were then placed in an incubator at 5% CO2, 80% humidity, and 37°C and shaken at 300 rpm
for 3 hours. TCD and viability measurements were taken after 1 hour, 2 hours, and 3 hours of
incubation and compared to original TCD and viability.
Results
Samples of a good lot of poloxamer (A) and two bad lots (B and C) were heat
treated to approximately 100°C. An additional sample of C was heat treated to 124°C. Post
heat treatment, samples were tested in the HSSF test.
All poloxamer samples treated to 100°C (as measured by RTD) showed no
improvement over untreated material of the same lot (. However, C heat treated to
124°C demonstrated a 19% increase in final viability compared to untreated C. Additionally,
the overall change in viability (i.e., final viability %, V , minus initial viability %, V ) for the
heat treated C was -27.4%, a 21% increase compared to untreated C (Table 2).
Table 2. Heat treated poloxamer samples, conditions, viability improvement over untreated
lot, and final viability in the HSSF test.
Viability
improvement over Viability @ 3hr
Sample Description Sample ID
untreated lot @3 (%)
Good lot, untreated A 0.0 85.6
Good lot, heat treated A_HT 1.8 87.4
Bad lot (B), untreated B 0.0 69.0
Bad lot (B), heat treated to
B_HT -5.4 63.6
100C
Bad lot (C), untreated C 0.0 49.0
Bad lot (C), heat treated to
C_HT -2.8 46.2
100C
Bad lot (C), heat treated to
C_HT_124C 21.8 68.0
124C
High shear shake flask model run with N=1
These results confirmed that heat treatment improved poloxamer performance in
cell culture and gave a preliminary indication of effective temperature and treatment duration.
However, these results suggest that temperatures higher than 100°C may be more effective in
heat-treating poloxamer for cell culture. It is thought that differences in temperature
measurement (e.g., the type of thermometer used to measure the temperature of poloxamer)
may result in different effective ranges for poloxamer heat treatment (see Example 8 for
further data and discussion).
Example 3: Transferring Heat Treatment to Ovens
A bench top drying oven was used as an alternative heating mechanism, which
provided temperature control and reproducibility. Additionally, the vacuum function allowed
the fumes released by the melting poloxamer to be siphoned out of the oven prior to opening
it and removing the heat treated poloxamer. Oven experiments were performed according to
the methods described in Example 2.
Initial experiments in the oven used a response surface design in order to test a
large range of conditions with minimal number of required samples (. The
temperature ranged from 92-148°C, with incubation times from 10-120 minutes. Samples of
a bad lot (C) were heat treated at specified conditions in an oven. Resulting samples were
then tested in the HSSF model to determine improvement in cell culture performance.
Poor performing poloxamer heated in an oven at 140°C for 60 minutes and 150°C
for 35 minutes showed substantial increases in final viability, equivalent to that of the
positive control in the HSSF test (and Table 3).
Table 3. Viability for poloxamer heated in an oven.
Averaged Viability
Averaged Standard Viability Improvement
Sample ID
Viability @ 3hr Deviation (SD)* improvement Standard
over untreated lot Deviation (SD)*
@3 hrs
Untreated bad lot
.4 11.1 0.0 0.0
Positive Control
88.4 2.5 58.1 13.6
C_100C, 10 min 40.5 3.9 10.1 15.0
C_100C, 60 min 42.6 8.1 12.2 3.0
C_120C, 35 min 42.1 1.0 11.8 10.1
C_140C, 10 min 46.7 0.1 16.4 11.2
C_140C, 60 min 89.7 0.4 59.4 10.7
C_150C, 35 min 91.6 0.5 61.2 11.6
* HSSF model run in duplicates
However, in these experiments, poloxamer heat treated at conditions below 140°C
and/or for less than 60 minutes showed no improvement in performance. These data indicated
that the minimum temperature of heat treatment to improve poloxamer performance was
approximately140°C at the durations of time tested. More extensive tests of temperature and
duration of heating are described below, e.g., in Example 5.
Example 4: Oven Heat Treatment DOE
The primary response surface map for heat treatment conditions in ovens
indicated the minimum temperature for effective heat treatment under the conditions tested
was approximately 140°C. The full design of experiments (DOE) was performed in ovens
according to the methods of Example 2 to determine the working range by going to very high
temperatures and long incubation times. The maximum temperature tested was 185°C and the
maximum incubation time tested for each temperature was 120 minutes. A bad lot of
poloxamer (G) was treated and tested in six-sample blocks which were segmented using a
Latin Square design. In total, three sample blocks and an additional six samples of conditions
of interest were treated (Table 4). These samples were then tested in the HSSF test to
determine cell culture performance.
Table 4. Heat treatment conditions evaluated in the full DOE in ovens. Temperatures ranged
from 110-185°C; duration ranged from 1-120 min. Boxes marked with a letter (corresponding
to blocks in Table 5) indicate treatment conditions that were tested, as listed in Table 5.
Time (min)
1 5 10 30 60 120
A D X F
125 D F A
140 F A X X D X
155 X D F A
170 F A D
185 D F A X
DOE raw data is shown in Table 5. The full DOE results, when mapped on a
contour plot, illustrated the large working range of heat treatment conditions that improve
poloxamer performance (.
Temperature (°C)
Table 5: Raw data from the full DOE experiment.
Viability
Improvement
Lot Time, Temperature, Viability
Block (over untreated
Number Min C @3 hrs
control average)
G 1 110 A 74.9 -4.8
G 5 140 A 77.1 -2.6
G 10 170 A 88.9 9.2
G 30 185 A 89.5 9.8
G 60 155 A 88.7 9.0
G 120 125 A 82.3 2.6
G 10 140 B 91.3 11.6
G 1 155 C 93.6 13.9
G 30 140 C 95.5 15.8
G 120 185 C 95.9 16.2
G 1 185 D 93.9 14.2
G 5 155 D 92.6 12.9
G 10 125 D 73.4 -6.3
G 30 110 D 51.9 -27.8
G 60 140 D 93.7 14.0
G 120 170 D 82.6 2.9
G 60 110 E 82.1 2.4
G 120 140 E 95.9 16.2
G 1 140 F 68.5 -11.2
G 5 170 F 94.5 14.8
G 10 185 F 95.6 15.9
G 30 155 F 95.2 15.5
G 60 125 F 68.2 -11.5
G 120 110 F 94.8 15.1
Samples heat treated at or above 155°C for all incubation times resulted in drastic
improvements in cell culture performance. In the HSSF test, these samples had changes in
viability less than 10% after 3 hr. At 140°C, heat treatment was not effective until incubation
time was at or above 30 minutes. Additionally, the lowest temperatures tested, 125°C and
110°C, were not effective until samples were incubated for 2 hours.
Example 5: Heat Treatment Robustness and Reproducibility
In order to demonstrate the reproducibility and robustness of the heat treatment
design space illustrated in key treatment conditions from the full DOE were
replicated using additional lots of poloxamer according to the methods described in Example
2. Two of these conditions were duplicated in order to address reproducibility. Selected
conditions fell inside or on the edge of the working range. In total, three bad lots were treated
(including G, which was previously used for the DOE) (Table 6). To ensure that heat
treatment would not be detrimental if performed on a good lot, one good lot was also treated
(E).
Table 6. Number of replicates for key heat treatment conditions tested across four poloxamer
lots.
Bad lot #1 Bad lot #2 Bad lot #3 Good lot
Temperature Time
(G) (H) (F) (E)
1 min 1 1 1 1
170C
min 1 1 1 1
1 min 3 2 2 2
155C
min 2 1 1 1
1 min 2 1 1 1
140C
min 3 2 2 2
The HSSF test results for the repeated treatment conditions were highly
comparable to results from the original DOE (Tables 7 and 8); however, there was observable
variability in optimal heat treatment conditions across bad lots (.
Table 7. Final cell viability for heat treatment conditions tested in the HSSF test on four lots
of poloxamer: E (good lot), F (bad lot), H (bad lot), and G (bad lot used in full DOE
experiments).
Sample E F G H
Untreated 92.2 72.7 78.8 77.5
140C, 30 min #1 93.8 89.8 91.5 77.3
140C, 30 min #2 96.1 89.8 89.5 90.6
140C, 1 min 95.3 90.8 90.0 90.7
155C, 1 min #1 95.2 90.2 90.8 84.1
155C, 1 min #2 94.8 89.9 90.7 81.5
155C, 30 min 96.0 91.0 89.5 92.4
170C, 1 min 95.5 87.4 90.6 93.4
170C, 30 min 94.0 89.2 89.4 92.0
Table 8. Change in cell viability (Vf – Vf ) in HSSF test for heat treatment
(treated) (untreated)
conditions tested on four different poloxamer lots: E (good lot), F (bad lot), H (bad lot), and
G (bad lot used in full DOE experiments).
Viability improvement over untreated lot @ 3 hr (%)
Lots
Sample E F G H
140C, 1 min 3.1 18.1 11.2 -0.2
140C, 30 min
1.6 17.1 12.7 13.1
140C, 30 min
3.9 17.1 10.7 13.2
155C, 1 min
3.1 17.5 12.0 6.6
155C, 1 min
2.6 17.2 11.9 4.1
155C, 30 min 3.8 18.3 10.7 15.0
170C, 1 min 3.3 14.7 11.8 15.9
170C, 30 min 1.8 16.5 10.6 14.5
High shear shake flask model run with N=1
Lots G and F, when treated at 155°C for 1 min or 140°C for 1 minute,
demonstrated a significant increase in cell culture performance. However, lot H showed no
improvement with treatment at 140°C for 1 minute, and only marginal (< 10%) improvement
with treatment at 155°C for 1 min. All other treatment conditions for this lot showed
significant improvement in cell culture. These results demonstrate that lots have slight
differences in minimum temperature and incubation time of heat treatment.
Example 6: Evaluation of Lower Temperatures and Long Duration
The heat treatment conditions described in Examples 2-5 were well above the
melting point of poloxamer. To determine if temperatures only slightly above the melting
point of poloxamer (~50°C) could have an effect on cell culture viability, samples of two bad
lots of poloxamer (H and G) were treated in ovens at 60°C and 80°C for 120 minutes and
then tested in the HSSF method according to Example 2.
Results for the heat treated samples demonstrated no significant improvement in
performance compared with untreated poloxamer, regardless of temperature (.
Without wishing to be bound to theory, it is hypothesized that longer incubation times may be
required for these lower temperatures to yield improved poloxamer.
Example 7: Heat Treatment in Vacuum
To determine the impact of oxygen on poloxamer heat treatment, samples of two
bad poloxamer lots (H and G) were heat treated to 140°C while under a slight vacuum in the
oven according to the methods in Example 2. Rather than removing samples from the
vacuum after a certain incubation time, the poloxamer was cooled in the oven under vacuum
down to room temperature to ensure that there was no external oxygen exposure while the
poloxamer was at the target temperature.
Table 9. Poloxamer heat treatment conditions and HSSF results for samples tested in a
vacuum.
Averaged
Viability
Averaged Standard Viability
Improvement
Sample ID Viability @ Deviation improvement
Standard
3hr (SD)* over untreated
Deviation (SD)*
lot @3 hrs
H (Untreated) 58.8 -37.5
0.0 0.0
H_60C 120 min 68.3 0.0 9.5 18.8
H_80C 120 min 63.4 9.4 4.6 9.4
G (Untreated) 80.0 -16.5
0.0 0.0
G_60C 120 min 77.2 2.5 -2.8 4.6
G_80C 120 min 74.8 0.1 -5.2 7.3
*High shear shake flask model run with N=2
Poloxamer treated in a vacuum demonstrated a significant improvement (> 20%
increase in final viability) over untreated poloxamer in cell culture ( Table 9). These
results demonstrate that external oxygen exposure during poloxamer heat treatment may not
be required to produce improved poloxamer.
Example 8: Temperature Measurement Using an RTD versus a Wire Thermocouple
Previous data supported a temperature range of 80-100°C for the heat treatment
process. However, the full DOE (e.g., as shown in supported an operating range at or
above 140°C.
An experiment was conducted examining the two different thermometers used to
measure poloxamer temperature during heat treatment. The experiments described in
Example 1 used an RTD, while a wire thermocouple was used in all oven experiments. The
RTD used requires an immersion depth of 4” for accurate temperature measurement.
Conversely, the wire thermocouple is designed to measure temperature precisely at its tip,
enabling it to accurately measure temperature while immersed in only a few millimeters of
poloxamer.
A side-by-side comparison was performed while heat treating poloxamer on a hot
plate according to the methods in Example 2. The wire thermocouple gave a temperature
reading of 152.6°C, whereas the RTD thermometer gave a reading of 81.65°C. Thus, the
RTD showed a significant under-measurement of temperature (> 70°C) when compared with
the thermocouple. These results demonstrate that different poloxamer temperature readings
underlie differences in effective temperature ranges sufficient for producing improved
poloxamer.
Example 9: Heating Ramp and Cooling Rate Characterization in Oven
Poloxamer samples, once placed in an oven, do not immediately reach target
temperature. The heating and cooling profiles for three temperatures used in the DOE were
evaluated in the oven according to the methods in Example 2.
Samples took an average of 18 minutes to reach target temperature (+/- 3°C) in
the oven with a standard deviation of 5.8 minutes (. Despite the variability in heating
times, the cooling rates were relatively similar. The average time for a sample to reach the
melting temperature of poloxamer (~40°C) was 7 minutes, with a standard deviation of 0.8
minutes. Assuming that the cooling profiles are largely linear, the cooling rates for samples
heated to 170C, 155C, and 140C were approximately -19°C/min, -19.5°C/min, and -
18°C/min, respectively.
Example 10: Statistical significance of viability and poloxamer heat treatment
A student’s t-test was used to determine the difference between the poloxamer
control lots’ performance in the HSSF tests and the significance of observed improvements in
cell culture performance. All HSSF control results from the oven DOE were included in the
data set. For heat treated samples, only samples within the working range were used to
calculate the mean change in cell viability post heat treatment. The working range was
defined to be conditions where change in viability in the HSSF test was less than 15%.
Treated and untreated poloxamers were compared using a student’s t-test ( α =
0.05) to determine statistically significant differences in means. Additionally, results of
treated material were compared to the positive control (D) results.
Table 10: Mean delta viability (Vf – Vf ) in the HSSF test for treated and
(treated) (untreated)
untreated poloxamer material of tested lots.
P value
Lot Mean Viability @ 3 hr Mean Viability@ 3 hr
Number (%), Untreated (%), Treated Untreated x
Treated
G 78.7 91.4 < 0.0001*
E 92.2 95.1 0.2490
F 79.3 89.8 < 0.0006*
H 67.9 91.8 <0.0001*
D 87.8 - -
With an alpha level of 0.05, mean comparisons between untreated bad lots of
poloxamer and the positive control lot (D) demonstrated significant differences (Table 10).
Post heat treatment, all lots performed significantly better than the positive control lot, with
the exception of H, which was comparable. Lot E, a good lot, had a p value > 0.05, indicating
its performance was not significantly different than the positive control lot. However, heat
treated poloxamer from lot E performed significantly better in the HSSF test than the positive
control (p value = 0.0005), demonstrating that the heat treatment process improved an already
acceptable lot.
These results are illustrated in , which displays treated and untreated
results of each lot compared to the overall positive control data set. For example,
illustrates that for bad lot G, the untreated G, the positive control good lot D, and the heat-
treated G were all statistically distinguishable, with the heat-treated G lot showing
significantly improved viability, as compared either to the positive control good lot (D) or the
untreated G bad lot.
Based on this analysis, cases where the heat treatment process was deemed
successful demonstrated an 18% improvement over untreated material. Furthermore, the
treated material performed at least as well, overall, as the positive control lot used in these
experiments.
Heat treating bad lots of poloxamer prior to use in cell culture media was an
effective method of improving their cell protection performance. Heat treatment was
effective at a wide range of temperatures and durations; however, the lower the temperature,
the longer the necessary treatment time. This process was robust, demonstrating similar
results across several poloxamer lots, and reproducible. While results presented here were
from experiments conducted in an oven, the process can be transferred to larger scale
equipment. The heat treatment process described herein can be transferred to any treatment
method which will ensure consistent heating of poloxamer for a required duration at the
necessary temperature.
Example 11: Statistical analysis of DOE Test data
The Examples described above demonstrate the effect of poloxamer heat
treatment on subsequent performance in cell culture (e.g., cell viability). Next, analyses were
undertaken to produce a transfer function, which is a mathematical model for the output
(viability @3hours in a shake flask model) as a function of the two dependent variables
(Temperature and Time).
DOE Test data (described in Table 12) gathered in an oven with temperature and
time as variables were analyzed in Minitab by Response Surface Regression method. A
known bad lot of Poloxamer (G) was heat-treated per DOE test design and tested in a High
Shear Shake Flask model used as a surrogate for shear protectant functionality. Higher
viability at the end of the 3 hour test indicates better performance of poloxamer. Similarly,
an evaluation between the same lot of poloxamer that has been treated to improve
performance compared to an untreated sample (negative control) was performed. To account
for intra lot variability observed in the poor performing lots, the average final viability of six
G controls was used as baseline to calculate the percentage of viability improvements
observed for each test case. Viability (%) at 3 hour and difference in treated vs untreated lots
(%) were the response variables. The results show that quality of this poor performing lot
can be improved as measured by increase in viability. The desired viability goal of positive
change in viability (treated lot- untreated lot) can be achieved at various temperature and time
treatments.
The analysis was performed with the change in viability (treated lot- untreated lot)
@ 3hrs. Since average final viability of one of the poor performing lot studied under stress
conditions, G was found to be 79.7 +/-5.0%, a 10% or 20% increase in viability was targeted
for the contour plot and for establishing minimum duration of heat treatment at a designated
temperature. It should also be noted that in case of another poor performer, C, lower
viabilities (44.8 +/-7.8%) than those seen for G may be expected for the untreated control.
Therefore, >35% improvement in viabilities for C may be expected at conditions where a
% augmentation was achieved for lot G. These results indicate that there exists linear
effect of temperature and time, interaction of temperature and time. The terms in the models
are statistically significant at 95% confidence level with P-value <0.05. The identification of
the optimum operating range and the factors in the model are unexpected and novel findings.
Table 12. Data set for lot G heat treatment.
Viability
Improvement
Lot Time, Temperature, Viability
(over untreated
Number Min C @3 hrs
control average)
1 110 74.9 -4.77
G 5 140 77.05 -2.62
170 88.9 9.23
G 30 185 89.5 9.83
60 155 88.65 8.98
G 120 125 82.25 2.58
140 91.3 11.63
1 155 93.6 13.93
140 95.5 15.83
120 185 95.85 16.18
G 1 185 93.9 14.23
155 92.6 12.93
G 10 125 73.4 -6.27
110 51.9 -27.77
60 140 93.7 14.03
120 170 82.6 2.93
60 110 82.1 2.43
G 120 140 95.9 16.23
1 140 68.5 -11.17
G 5 170 94.5 14.83
185 95.6 15.93
G 30 155 95.2 15.53
60 125 68.15 -11.52
120 110 94.75 15.08
G 1 140 91.5 11.83
140 89.5 9.83
G 30 140 90 10.33
1 155 90.8 11.13
G 1 155 90.7 11.03
G 30 155 89.5 9.83
1 170 90.6 10.93
G 30 170 89.4 9.73
120 60 77.2 -2.47
G 120 80 74.7 -4.97
HSSF model run in duplicates
For analysis software, Minitab version 17.1 (Minitab.com, State College PA) was
used. Analysis was Regression analysis (RSRegress). Response surface regression was used
to analyze viability improvement (over untreated lot) versus Time (min) and Temperature
(ºC).
The analysis of variance, model summary, and coded coefficients are provided
below in Tables 13-15.
Table 13. Analysis of Variance.
Source DF Adj SS Adj MS F-Value P-Value
Model 5 1666.90 333.38 5.29 0.002
Linear 2 1369.54 684.77 10.87 0.000
Time, min 1 484.39 484.39 7.69 0.010
Temp., ºC 1 1356.83 1356.83 21.54 0.000
Square 2 203.14 101.57 1.61 0.217
(Time, min) 1 12.47 12.47 0.20 0.660
(Temperature, C) 1 201.47 201.47 3.20 0.085
2-Way Interaction 1 432.89 432.89 6.87 0.014
(Time, 1 432.89 432.89 6.87 0.014
min)*(Temperature,
Error 28 1764.05 63.00
Lack-of-Fit 22 1455.72 66.17 1.29 0.403
Pure Error 6 308.33 51.39
Total 33 3430.94
Table 14. Model Summary.
S R-sq R-sq(adj) R-sq(pred)
7.93736 48.58% 39.40% 8.41%
Table 15. Coded Coefficients.
Term Effect Coef. SE Coef. T-value P-value VIF
Constant 1.59 3.01 0.53 0.602
Time, min 16.01 8.01 2.89 2.77 0.010 2.49
Temp., ºC 41.89 20.94 4.51 4.64 0.000 2.31
(Time, min) 3.32 1.66 3.73 0.44 0.660 1.08
(Temperature, C) -22.36 -11.18 6.25 -1.79 0.085 2.37
(Time, -24.78 -12.39 4.73 -2.62 0.014 2.22
min)*(Temperature,
Based on these results, a regression equation (in uncoded units) was determined
as: Viability Improvement (over untreated lot),% = -113.5 + 0.486*(Time, min)
+ 1.238*(Temperature, C) + 0.00047*(Time, min) -0.00286*(Temperature, C) -
0.00333*(Time, min)*(Temperature, C)
The transfer function shown above predicts the improvement in viability for lot G
over untreated control as a function of heat treatment temperature and duration. It also
contains second order terms involving temperature and time and their interaction. Using the
above model, expected viability for a test case (not derived empricially) can be obtained. A
sample output prediction is shown below for test conditions 157ºC and 1 minute:
Viability improvement = -113.5 + (0.486 *1) + (1.238 *157) + 0.00047 *1^2) –
(0.00286 *157^2) – (0.00333 *1*157) = 10.3%
The experimental data was used to generate the contour plot shown in
(empirical data shown in black circles). Based on the model generated by the regression, 5
points can be inferred mathematically.
First, the treatment response can be classified into three temperature zones (157°C
-185°C). (134°C -157°C) and (60°C-134°C).
Second, in the high temperature zone of 157°C -185°C, viabilities of heat treated
lots can be improved from 1 to 20% within a minimum heat treatment of one minute.
Third, in the mid temperature zone of 134°C -157°C, viabilities of heat treated lots
can be improved between 1 and 10% within a minimum heat treatment duration of 1 minute.
Viabilities can be enhanced up to 20% with a minimum heat treatment duration of 120
minutes.
Fourth, in the low temperature zone of 60°C -134°C, viabilities of heat treated lots
can be improved up to 10% within a heat treatment duration of 140 minutes. Viabilities can
be enhanced up to 20% with a minimum heat treatment duration of 164 minutes. It is to be
noted that the durations described for the mid and low temperature zones are simplified
guidelines. For example, as shown in , the temperatures of 60°C, 80°C, 120°C within
the low temperature zone require 164 minutes, 147 minutes, and 115 minutes, respectively, to
achieve at least a 10% improvement in viability. Exemplary values are described in Table 16
below.
Table 16. Exemplary temperatures, times, and corresponding viability improvements.
Min Time
Min Time
Min Time required required for
required for light
Temp Range, for dark grey zone dark grey zone
grey zone (1-10%)
ºC (10-20%) (>20%)
improvement,
improvement, min improvement,
60 143 164 186
80 122 147 175
100 98 132 166
120 62 115 162
134 1 102 163
157 1 1 NA
185 1 1 NA
Fifth, the model set forth above was derived from data generated with lot G.
Since the untreated control had a higher baseline viability of 79%, viability improvements
can be realized to a maximum of 20%. However, for lots such as C, where the untreated lot
had a much lower viability of 45%, higher levels of improvement can be realized. For
example, in the mid temperature zone of 134°C -157°C , viability can be improved by 42%
within a heat treatment duration of 15 minutes for lot C. The observed differences in
performance between lots C and G are summarized in Table 17 below.
Table 17. Summary of C and G performance
Sample Sample
Parameter Viability (%) Parameter Viability (%)
@3 hr @3 hr
Average 44.8 Average 79.7
Stdev 7.4 Stdev 5.0
N 6 N 6
Therefore, the heat treatment value is more pronounced in lots such as C. A full
data set for this lot could not be performed due to lack of raw material to run a full set of
experiments. G represents a marginally poor performing lot and the model predicted above
can be considered conservative. The data generated using lots C and G demonstrate that heat-
treating poloxamer may improve the performance of other poloxamer lots not tested here.
The improvements in performance may be affected by time and temperature as described
above. The results described above demonstrate that increasing temperature shortens the
duration of heat treatment required to improve poloxamer performance, and that lower
temperatures may be used to improve poloxamer performance over longer durations.
Without wishing to be bound to theory, it is thought that the precise percentage of viability
improvement observed upon heat treatment will depend upon the baseline viability observed
for a particular poloxamer lot before heat treatment.
Claims (28)
1. A method of preparing a poloxamer for use in a cell culture medium, comprising the steps of: (a) heating a solid poloxamer to at least about 60ºC to form a liquid poloxamer, wherein the poloxamer is heated to: (1) between 157ºC and 185°C for at least 1 minute, (2) between 134ºC and 157ºC for at least 1 minute, (3) between 120ºC and 134ºC for at least 62 minutes, (4) between 100ºC and 120ºC for at least 98 minutes, (5) between 80ºC and 100ºC for at least 122 minutes, or (6) between 60ºC and 80ºC for at least 143 minutes; and (b) cooling the liquid poloxamer to a temperature below about 50ºC to form a solid heat-treated poloxamer, wherein the cooling is not conducted in a prilling or milling device, and wherein the poloxamer comprises a copolymer of ethylene oxide and propylene oxide.
2. The method of claim 1, wherein cell viability in a cell culture medium comprising the heat-treated poloxamer is increased as compared to cell viability in a cell culture medium comprising the poloxamer before step (a).
3. The method of claim 1, wherein the poloxamer is heated to between about 157ºC and about 185°C for between 1 minute and about 250 minutes.
4. The method of claim 1, wherein the poloxamer is heated to between about 134ºC and about 157ºC for between 1 minute and about 250 minutes.
5. The method of claim 1, wherein the poloxamer is heated to between about 120ºC and about 134ºC for between about 62 minutes and about 250 minutes.
6. The method of claim 1, wherein the poloxamer is heated to between about 100ºC and about 120ºC for between about 98 minutes and about 250 minutes.
7. The method of claim 1, wherein the poloxamer is heated to between about 80ºC and about 100ºC for between about 122 minutes and about 250 minutes.
8. The method of claim 1, wherein the poloxamer is heated to between about 60ºC and about 80ºC for between about 143 minutes and about 250 minutes.
9. The method of claim 1 or claim 2, wherein cell viability in a cell culture medium comprising the heat-treated poloxamer is increased by at least 10% as compared to cell viability in a cell culture medium comprising the poloxamer before step (a).
10. The method of claim 9, wherein the cell viability is increased by at least about 20%.
11. The method of claim 9, wherein the cell viability is increased by at least about 30%.
12. The method of any one of claims 1-11, wherein the cell viability in a cell culture medium comprising the poloxamer before step (a) is below about 80% after about 3 hours of cell culturing.
13. The method of any one of claims 1-12, wherein the liquid poloxamer in step (b) is cooled at ambient temperature, about 2ºC to about 8ºC, or below 0ºC.
14. The method of any one of claims 1-13, wherein the poloxamer is heated under a vacuum.
15. The method of any one of claims 1-14, wherein the liquid poloxamer is cooled for at least about 20 minutes.
16. The method of any one of claims 1-15, wherein the heated-treated poloxamer produced in step (b) is added into a cell culture medium.
17. The method of any one of claims 1-16, wherein steps (a) and (b) are repeated at least once before adding the heated-treated poloxamer into the cell culture medium.
18. The method of any one of claims 1-17, wherein the poloxamer has been treated by a prilling process before step (a).
19. The method of any one of claims 1-18, wherein the poloxamer has a formula of HO(C H O) (C H O) (C H O) H, wherein n is from about 60 to about 150 and m is 2 4 n 3 6 m 2 4 n from about 25 to about 60.
20. The method of any one of claims 1-19, wherein the poloxamer has a melting temperature of about 55ºC.
21. The method of any one of claims 1-20, wherein the poloxamer has an average molecular weight of from about 6,000 to about 18,000 Daltons.
22. The method of any one of claims 1-20, wherein the poloxamer comprises a copolymer having a formula of HO(C H O) (C H O) (C H O) H with n having a value of about 2 4 n 3 6 m 2 4 n 80, with m having a value of about 27, and the poloxamer has an average molecular weight of from about 7680 to about 9510 g/mol.
23. The method of any one of claims 1-20, wherein the poloxamer is poloxamer 188.
24. The method of any one of claims 1-23, wherein the cell is a mammalian cell.
25. The method of claim 24, wherein the cell is a Chinese Hamster Ovary (CHO) cell.
26. The method of any one of claims 1-25, wherein the cell is an insect cell.
27. The method of any one of claims 1-26, wherein the cell produces a polypeptide.
28. A method of producing a polypeptide in a cell culture, comprising: (a) heating a solid poloxamer to at least about 60ºC to form a liquid poloxamer, wherein the poloxamer is heated to: (1) between 157ºC and 185°C for at least 1 minute, (2) between 134ºC and 157ºC for at least 1 minute, (3) between 120ºC and 134ºC for at least 62 minutes, (4) between 100ºC and 120ºC for at least 98 minutes, (5) between 80ºC and 100ºC for at least 122 minutes, or
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461970281P | 2014-03-25 | 2014-03-25 | |
US61/970,281 | 2014-03-25 | ||
PCT/US2015/022592 WO2015148736A1 (en) | 2014-03-25 | 2015-03-25 | Methods of preparing a poloxamer for use in cell culture medium |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ725151A NZ725151A (en) | 2021-05-28 |
NZ725151B2 true NZ725151B2 (en) | 2021-08-31 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11912823B2 (en) | Methods of preparing a poloxamer for use in cell culture medium | |
JP7377316B2 (en) | Methods for harvesting mammalian cell cultures | |
JP7066775B2 (en) | Process for manipulating levels of glycoprotein glycan content | |
JP6993083B2 (en) | Virus inactivation method using environmentally friendly cleaning agent | |
AU2023200660A1 (en) | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors | |
KR20170007457A (en) | Controlling the formation of disulfide bonds in protein solutions by adding reducing agents | |
NZ725151B2 (en) | Methods of preparing a poloxamer for use in cell culture medium |